Issuu on Google+

CANCER THERAPY & RESEARCH CENTER 2016 ANNUAL REPORT

The Silver Lining


OUR MISSION The mission of the CTRC is to reduce the cancer burden in South Texas through the highest quality cancer care; groundbreaking research aimed at reducing the incidence and mortality of cancer; education of future cancer scientists and clinicians; and cancer prevention programs focused on our unique population.

DIRECTOR

Ian M. Thompson Jr., M.D.

DEPUTY DIRECTOR Tim H. M. Huang, Ph.D.

CONTRIBUTING WRITERS Mary Burch Leticia De Los Santos Catherine Duncan Mary Jackson Kate Lathrop, M.D. Georgia McCann, M.D. Lori Moctezuma Sheri Ortiz Susan Padalecki, Ph.D. Ian M. Thompson Jr., M.D.

MANAGING EDITOR Catherine Duncan

DESIGN & PRODUCTION Kris Enders Doyle

PRINTING UT Print

Photos provided by Noell Vidaurri, Creative Media Services/Marketing and Catherine Duncan, Institutional Advancement 7979 Wurzbach Rd. San Antonio, TX 78229 210-450-1000

www.ctrc.net

THE SILVER LINING The term silver lining emphasizes the brighter side of a situation that may seem gloomy on the surface. Often, the phrase “every cloud has a silver lining” is used when someone is trying to find a positive aspect of even the worst event or situation. If we look at the right time, a dark rain cloud will have a silver edge or lining. After the rain ends, we know the sun will return.


About the cover The Cancer Therapy & Research Center (CTRC) brings hope to all who enter its doors. Physicians, nurses, staff, students and volunteers are ready and waiting to offer the best treatments, the brightest smiles, the biggest hugs and the strength to thrive to all cancer patients. Through some of the most difficult times, we look for the silver lining to share with patients and family members. We instill hope and the knowledge they are not in this alone. The silver lining, our CTRC, is the place where people come to receive the best possible treatments with the best possible outcomes.

The University of Texas Health Science Center San Antonio (UT Health San AntonioTM) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. UT Health San Antonio does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. Language assistance services are available to you free of charge. Contact the clinic where you will be treated or call 210-450-6101. Español (Spanish)

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 210-450-6101. Tiếng Việt (Vietnamese)

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 210-450-6101.

4

GREETINGS

7 8

CTRC BY THE NUMBERS OUR TEAM

10

13 14 20

Ian M. Thompson Jr., M.D. ________________________ 4 William L. Henrich, M.D. _ ________________________ 5 CTRC Leadership________________________________ 6

Brightening Patients’ Days ________________________ 8 Making Sense of Healthy Foods_ ___________________ 9 New Faculty _ __________________________________ 10

28

CLINICAL TRIALS

30

SERVICE OUTREACH

34

COMMUNITY IMPACT

40

CTRC COMMUNITY LEADERSHIP

EDUCATION NCI-Funded Partnership Concentrates on Cancer ____ 10 Bladder Cancer Cell Breakthrough___________________11 High School Student Designs Tool __________________11 Professor and Student Make Discovery ______________11 Local Teenager Earns CTRC Distinguished Science Award ________________________________ 12 Major Grant Provides Huston-Tillotson Students Experience in Prostate Cancer Research ___________ 12

CTRC CELEBRATES 25 YEARS WITH ESTEEMED NCI DESIGNATION PATIENT CARE A Turn for the Better _ ___________________________ 14 Adding to the Arsenal____________________________ 16 Cancer Genetics and High-Risk Screening Clinic _____ 17 Teacher and Student Reunite Through Spirit of Giving ________________________ 17 Skin Cancer: A Clear Margin for Success _ __________ 18

RESEARCH One Giant Leap Against Cancer ___________________20 CPRIT Awards Funding _ _________________________ 21 Discovery of the Year_ ___________________________ 22 Clinical Investigator of the Year _ __________________ 23 CTRC Investigators Working on SPORE Grants_______ 24 POETIC Justice _________________________________ 26 Presidential Junior Research Scholar________________ 27 CTRC Council Supports Innovative Pilot Study_______ 27

44 46

CTRC Leader in Worldwide Cancer Clinical Trials Network ___________________ 28 Clinical Trials Give Patient Hope of Longer Life with Lung Cancer__________________ 28 CTRC Offers Large Variety of Cancer Clinical Trials in South Texas ____________ 29

CTRC Happily Goes to the Dogs _ _________________30 Above and Beyond ______________________________ 32 Finding a Soul Friend _ ___________________________ 32 Keeping in Tune with Patients _____________________ 33 Volunteer of the Year - Loyce Holt _________________ 33

Colon Cancer Awareness _ _______________________34 CTRC Hosts First Give Cancer the Boot Run/Walk ___34 Honoring Loved Ones _ __________________________ 35 Pilot Projects Funded ____________________________ 35 Circles of Hope Come to CTRC _ __________________ 36 Circle of Hope Supports Pilot Colon Research Study __________________________ 36 Book & Author Luncheon Celebrates Milestone _ _________________________ 37 Thanks to Our Community _______________________ 38 Cordillera Ranch CTRC Research Circle _____________ 39 A Lasting Legacy _ ______________________________ 39

CTRC Board of Governors ________________________40 CTRC Foundation _______________________________42 CTRC Council __________________________________42 CTRC Council Builds on Successful Tradition ________43

MAJOR GIFT HIGHLIGHTS COMMUNITY GIVING

Cancer Therapy & Research Center

n

Annual Report 2016 n

3


IAN M. THOMPSON JR., M.D. DIRECTOR, CANCER THERAPY & RESEARCH CENTER

Mays Family Foundation Distinguished University Presidential Chair for the Director of the CTRC Glenda & Gary Woods Endowed Chair in GU Oncology Doctors Hospital at Renaissance Distinguished University Chair in Urology Professor of Urology

A MESSAGE FROM THE DIRECTOR It is an honor to publish our 2016 Cancer Therapy & Research Center Annual Report. We owe a tremendous debt of gratitude to the team who assembled the report. I am so proud of the work of my colleagues. If we did justice to all of them and their work, this report would come to you in several volumes and hundreds of pages. Their efforts span so many areas from exceptional clinical care by our physicians, nurses and staff, to amazing scientific discoveries in our cancer center laboratories, to transformative clinical trials – many of which will be cancer cures of tomorrow – to cancer prevention services across South Texas, to educating the next generation of scientists and physicians. We have a tremendous responsibility to the legacy of the CTRC to advance the groundbreaking discoveries and to deliver the highest quality care to our patients. The needs of our patients and the citizens of South Texas are daunting, and with our commitment, we acknowledge the urgency of our mission. On behalf of our patients and their families, our deepest thanks to everyone who has helped make these accomplishments possible. Sincerely,

Ian M. Thompson Jr., M.D.

4

n

Cancer Therapy & Research Center

n

Annual Report 2016


WILLIAM L. HENRICH, M.D., MACP PRESIDENT, UT HEALTH SCIENCE CENTER SAN ANTONIO

Professor of Medicine

WITH SPECIAL THANKS FROM THE PRESIDENT It is my privilege, on behalf of The University of Texas Health Science Center at San Antonio, to congratulate the Cancer Therapy & Research Center (CTRC) – and our community – on the exceptional accomplishment of 25 years as a National Cancer Institute (NCI)-Designated Cancer Center. Our nation’s NCI-designated cancer centers deliver cutting-edge cancer treatments to patients in communities across the United States, and the CTRC is one of only four cancer centers in Texas to earn this prestigious designation. The CTRC’s 25-year designation recognizes its outstanding scientific leadership and the depth of its research program. As we celebrate a rich 42-year history of success at the CTRC, we look forward to the next chapter in our commitment to providing the best cancer care available to the citizens of our community and South Texas. As we undertake an exciting new affiliation between the Health Science Center CTRC and The University of Texas MD Anderson Cancer Center, we join two NCI-designated cancer centers together for the first time in this battle against cancer. One of the highest benefits of our partnership will be the combined knowledge, research and patient care that CTRC and MD Anderson together will bring to the people of San Antonio, Texas and the world. It will yield new opportunities – and hope – that benefit patients and their families. As we have throughout out 42-year history, that promise will be realized because of each of you who have invested in San Antonio’s cancer center – the CTRC, and through your support, the real hope for a future without cancer.


SENIOR LEADERSHIP

LEADERSHIP Rong Li, Ph.D. Cancer Development and Progression Program Co-Leader

Ian M. Thompson Jr., M.D. Director

6

n

Tim H. M. Huang, Ph.D. Deputy Director

Tyler Curiel, M.D., Ph.D. Cancer Development and Progression Program Co-Leader

Virginia Kaklamani, M.D., D.Sc. Associate Director Clinical Research

Susan Mooberry, Ph.D. Experimental and Developmental Therapeutics Program Co-Leader

Susan Padalecki, Ph.D. Associate Director Research Administration

Andrew Brenner, M.D., Ph.D. Experimental and Developmental Therapeutics Program Co-Leader

Amelie Ramirez, Dr. P.H. Associate Director for Population Sciences

Gail Tomlinson, M.D., Ph.D. Population Science & Prevention Program Co-Leader

Luzhe Sun, Ph.D. Associate Director Translational Research

Pratap Kumar, Ph.D. Population Science & Prevention Program Co-Leader

Cancer Therapy & Research Center

n

Annual Report 2016

Peter Houghton, Ph.D. Director, Greehey Children’s Cancer Research Institute Patty McCarroll Senior Director, Finance and Administration Anand Karnad, M.D. Chief, Division of Hematology/ Oncology Deborah Ivy Director, Patient Financial Services Ivan Reveles, Pharm.D. Pharmacy Supervisor Denise Hicks Director, Laboratory Mary Burch Senior Director, Development Sheri Ortiz Senior Director, Development Cynthia Smith Director, Financial Operations Melissa Nashawati Director, Quality Assurance Division Susan Johnson Director, Clinical Trials Office Richard Markow Director, SABCS Robin Leach, Ph.D. Director, Scientific Development Laura Gonzales, B.S.N., RN Clinic Manager Kristie Foster Director, Practice Operations

ctrc team Co-Director, X-ray P. John Hart, Ph.D. Co-Director, MMI Eileen Lafer, Ph.D. Technical Director, NMR Kristen Cano, Ph.D. Technical Director, X-ray Alex Taylor, Ph.D. Technical Director, MMI Liping Wang, Ph.D.

John Sarantopoulos, M.D. Phase 1 Oncology Anand Karnad, M.D. Sarcoma Laura Tenner, M.D. Special Populations Woondong Jeong, M.D. Thoracic Oncology

DEPARTMENT CHAIRS MASS SPECTROMETRY Pam Otto, M.D. Director Professor and Chairman, Radiology Susan Weintraub, Ph.D. John H. Calhoon, M.D. Technical Director, Metabolomics Xiaoli Gao, Ph.D. Professor and Chairman, Cardiothoracic Surgery Research Core Facility Technologist-Sr. W. Brian Reeves. M.D. Sam Pardo Professor and Chairman, Medicine Research Core Facility Technologist Dana Molleur Ismail Jatoi, M.D., Ph.D. Professor and Chief, Surgical Oncology NEXT GENERATION SEQUENCING & Endocrine Surgery AND BIOINFORMATICS Co-Director, Sequencing Chul S. Ha, M.D. Zhao Lai, Ph.D. Professor and Chairman, Radiation Oncology Co-Director, Bioinformatics Ron Rodriguez, M.D., Ph.D. Yidong Chen, Ph.D. Professor and Chairman, Urology Bioinformatician Yi Zou, M.S. Deborah L. Conway, M.D. Technical Director, Sequencing Associate Professor and Interim Chairman Dawn Garcia, M.S. Obstetrics & Gynecology OPTICAL IMAGING Randal A. Otto, M.D., FACS Director Professor and Chairman, Otolaryngology James Lechleiter, Ph.D. Co-Director Frank Miller, M.D., FACS Exing Wang, Ph.D. Professor and Deputy Chairman, Otolaryngology Imaging Technologist Director, Head and Neck Surgery Jimmy Wewer SHARED RESOURCES Glenn A. Halff, M.D. BIOSTATISTICS MULTIDISCIPLINARY Director, UT Transplant Center and Professor, Surgery Director CLINIC LEADERS David F. Jimenez, M.D. Jonathan Gelfond, M.D., Ph.D. Virginia Kaklamani, M.D., D.Sc. Chairman, Neurosurgery Co-Director Breast Center Joel Michalek, Ph.D. Robert H. Quinn, M.D. John Sarantopoulos, M.D. FLOW CYTOMETRY Professor and Chairman, Orthopaedics Cutaneous Oncology Director Anne-Marie Langevin, M.D. Devalingam Mahalingam, M.D., Ph.D. Benjamin Daniel, Ph.D. Professor, Pediatric Hematology/Oncology Gastrointestinal Oncology Technical Director Robert Svatek, M.D. Gail Tomlinson, M.D., Ph.D. Karla Gorena Genitourinary Oncology Chief, Pediatric Hematology/Oncology GENOMICS Tyler Curiel, M.D., Ph.D. Director Howard T. Wang, M.D. Gynecologic Oncology Robin Leach, Ph.D. Chief, Plastic & Reconstructive Surgery Woondong Jeong, M.D. Co-Director Anand Karnad, M.D. Head & Neck Oncology Teresa Johnson-Pais, Ph.D. Chief, Hematology/Oncology Research Associate Anand Karnad, M.D. Hematologic Malignancies John Sarantopoulos, M.D. Mandy Hinojosa Interim Director, Institute Andrew Brenner, M.D., Ph.D. MACROMOLECULAR STRUCTURE for Drug Development Neuro-Oncology & INTERACTIONS Sandra S. Osswald, M.D. Director, MSISR, NMR Anne-Marie Langevin, M.D. Pediatric Hematology/Oncology Dmitri Ivanov, Ph.D. Chief, Dermatology and Cutaneous Surgery


CTRC by the Numbers 159

Did you know…

Cancer center members

180+

CTRC has more than 85 providers caring for CTRC’s patients?

Open clinical trials

CTRC has 105 full members and 54 associate members all focused on finding new and better ways to prevent, understand and treat cancer?

1,500+

Accrual to clinical trials CTRC has more than 180 clinical trials on average open to our patients each year?

3,300+

New patients CTRC members brought in more than $34 million in extramural grants in 2016? CTRC clinicians conducted more than 80,000 patient visits in 2016? CTRC saw more than 3,300 newly diagnosed cancer patients in the past year? Each year, CTRC sees patients from all over Texas, the U.S. and around the globe? CTRC supports 8 shared resource laboratories that provide members with access to state-of-the-art technology to assist with their research? Last year, CTRC gave more than 1,500 patients the opportunity to participate in clinical trials—where the newest life-saving therapeutics and techniques are tested and developed?

CTRC use of funds by type:

Salaries & Benefits Supplies & Equipment Outside Services Other

39% 39% 16% 6%

CTRC funding source:

Patient Revenue Grants/Contracts Contributions Other

Cancer Therapy & Research Center

43% 37% 18% 2%

n

Annual Report 2016 n

7


our team

Brightening patients’ days with smiles, hugs and music

P

amla Hernandez, front desk receptionist at the Radiation Oncology Clinic, said she understands that patients and their families do not want to be at the Cancer Therapy & Research Center (CTRC). No one wants to receive a cancer diagnosis or to see their loved ones go through cancer treatment.

Pamla Hernandez with Dr. Ian Thompson

That is why she took it upon herself to bring joy, friendliness and inspiration to CTRC patients, their family members and caregivers during the time they spend in her area on the second floor of the Grossman Building. “I try to make them feel like family. I treat them how I would want my family members treated – with dignity and respect,” she said. Hernandez, who has worked at the CTRC for six years, said she tries to do little things to brighten a patient’s day. She has a board with an inspirational quote that she changes each day. On Fridays, she plays music so they can kick off the weekend on a high note. “We play music the patients bring in or they request. We interact a lot and discuss the music and memories connected to certain songs. They like a lot of the oldies but goodies,” she said. “We have patients who literally dance in the lobby.” Hernandez, whose patients range in age from infants through senior citizens, describes the CTRC patients as “amazing. They are the best.” Hernandez said she is fulfilled every day when the patients smile or laugh. “That means for a little while they aren’t thinking about cancer. I am just blessed to have my job.” Lowell Glassburn, M.H.A., director of finance and administration for radiation oncology, said the CTRC is fortunate to have Hernandez as an exceptional employee. “The patients love her. She makes them feel welcome and accepted,” he said. “She does a lot of little things like decorating the waiting area. Pam tries to cheer them up and help them forget why they are there.” Glassburn said Hernandez and the patients often develop a personal relationship because some patients receive treatment for 40 consecutive days. “They get to know each other. Pam knows who needs a hug and who just wants to talk. She really cares about each patient.”

8

n

Cancer Therapy & Research Center

n

Annual Report 2016


Making sense of healthy foods

B

reanna Price specializes in table talk. However, her conversations are not idle dinner chatter. She offers expert advice on healthy eating to patients battling cancer.

As the registered dietitian at the Cancer Therapy & Research Center (CTRC), Price assists patients undergoing treatment as well as those who have completed treatments. “I love food and cooking,” she said. “I enjoy giving patients advice on meal planning and healthy eating to help them cope with the effects of cancer and their treatment.” Price provides one-on-one nutrition counseling, tailoring diet recommendations for each patient’s needs. Some struggle with weight loss while others may be dealing with swallowing issues, Price explained. “Every patient has different needs.” The Texas native, who grew up in a small town near Victoria, is a licensed dietitian, certified by the state of Texas. She earned a Master of Dietetics Studies from the UT Health Science Center San Antonio and a Bachelor of Science in Biology from The University of Texas at San Antonio.

Breanna Price

During college, Breanna surveyed diets and was involved in a research study that served meals to seniors. Her early experiences motivated her to pursue the “clinical side” of a healthy diet. She applies her knowledge to each individual patient. “I work with those going through treatment as well as survivors,” she said. “Those who have completed treatments want to know how to prevent a recurrence of the disease.” Some patients suffer from severe weight loss. Others may be taking their nourishment through a feeding tube. Each case requires a specialized diet – not some cookie-cutter approach, she said. That is where Price excels. “The needs vary with each patient. I consult with the referring CTRC doctors to make sure that the dietary plan is right for that particular patient.” Her duties also include operating the CTRC’s Nutritional Supplement Assistance Program and overseeing the closed pantry project in cooperation with the San Antonio Food Bank and CTRC Council volunteers. The closed pantry is solely for patients receiving treatment at the CTRC. “We have patients who can’t afford to purchase the food they need,” Price said. “We have nutritious food on-site that we can give to patients to help with the cost of groceries.”

Cancer Therapy & Research Center

n

Annual Report 2016 n

9


NEW CTRC FACULTY Alex Mejia-Garcia, M.D. Assistant Professor Department of Medicine Division of Hematology/Oncology Clinical specialties: Hematology/oncology, internal medicine Research interests: Clinical trials, Phase I, hematologic malignancies, experimental and developmental therapeutics program

Education

Elizabeth Bowhay-Carnes, M.D. Assistant Professor Department of Medicine Division of Hematology/Oncology Clinical specialties: Hematology/oncology, internal medicine, cancers of the blood, non-malignant disorders of the blood, and cancer of the soft tissue or bone Zhijie “Jason” Liu, Ph.D. Assistant Professor Department of Molecular Medicine Research interests: Understanding how signal-dependent gene programs are regulated in cell differentiation/ dedifferentiation and in the development of cancer and other diseases. Kexin Xu, Ph.D. Assistant Professor Department of Molecular Medicine Research interests: Seeking to understand the fundamental roles of the epigenome in control of the context-specific transcriptional programs and how this control contributes to normal development or cancer progression. Victor Jin, Ph.D. Associate Professor Department of Molecular Medicine Research interests: Computational Biology – to apply machine learning algorithms and statistical methods to decipher the transcriptional regulatory codes in eukaryotic genomes. Translational Bioinformatics – to develop computational pipelines to aid molecular biomarker discovery.

10

n

Cancer Therapy & Research Center

n

Annual Report 2016

Students from The University of Texas at San Antonio (UTSA) participated in the Cancer Bioinformatics Initiative, a partnership between the UT Health Science Center San Antonio and UTSA and funded by the National Cancer Institute.

NCI-FUNDED PARTNERSHIP CONCENTRATES ON CANCER, HEALTH DISPARITY RESEARCH The Cancer Bioinformatics Initiative, a partnership between the CTRC at the UT Health Science Center San Antonio and UT San Antonio, is a National Cancer Institute-funded effort to train students from quantitative fields such as computer science, statistics, and related disciplines in cancer biology. Led by Robin Leach, Ph.D., professor of cell systems and anatomy at the Health Science Center, and Kay Robbins, Ph.D., professor of computer science at UTSA, this unique program matches each undergraduate and master’s level student from UTSA with a UT Health Science Center cancer researcher as well as a UTSA faculty member from the student’s home department. Participants engage in research as part of an ongoing cancer/health disparity research project, attend seminars, actively participate in a student journal club, and tour research divisions at the Health Science Center.


STUDENT, FACULTY COLLABORATION RESULTS IN BLADDER CANCER CELL BREAKTHROUGH Neelam Mukherjee, Ph.D., postdoctoral fellow, worked with Rita Ghosh, Ph.D., assistant professor of urology at the UT Health Science Center San Antonio, on Dr. Mukherjee’s dissertation work in which she studied the role of a protein, SETD6 methyltransferase, in bladder cancer and showed for the first time that SETD6mediated non-histone protein lysine methylation of p65 plays an important role in bladder cancer cell survival. Drs. Rita Ghosh (left) and Neelam Mukherjee

After her graduation, Dr. Mukherjee began her career as a postdoctoral fellow in the Department of Urology in the laboratory of Robert Svatek, M.D., assistant professor of urology at the Health Science Center and bladder cancer surgeon with UT Medicine San Antonio. Dr. Mukherjee is characterizing the function of myeloid cells in bladder cancer therapeutic intervention with Bacillus Calmette-Guérin (BCG).

HIGH SCHOOL STUDENT DESIGNS WORKLOAD ASSESSMENT TOOL

Finley was able to run test data to help him map out the real-world work life of a clinical oncology study coordinator.

COLLABORATION WITH PROFESSOR HELPS STUDENT MAKE PROSTATE CANCER DISCOVERY Huiyoung “Jimmy” Yun, Ph.D., joined the laboratory of Pratap Kumar, Ph.D., professor of urology at the UT Health Science Center San Antonio, for his graduate studies. Dr. Yun’s studies led to the demonstration that loss of aldo-keto reductase (AKR1C1) and estrogen receptor beta (ERβ) contributes to castrate resistant prostate cancer by inhibiting apoptosis through transcriptional up regulation of the anti-apoptotic protein, c-FLIP. These data provide first-time evidence for ERβ-mediated transcriptional upregulation Drs. Pratap Kumar and Huiyoung “Jimmy” Yun of c-FLIP as an underlying mechanism for development of aggressive castrate resistant cancer. Therefore, targeting ERβ and Sp-mediated c-FLIP regulation could have therapeutic potential especially for men with high levels of estrogens.

Mark Finley, a student at Sandra Day O’Connor High School in San Antonio ’s Northside Independent School District, was interested in oncology for part of an Independent Study Mentorship Course. Working with Christina Spencer, a study coordinator in the Clinical Trials Office at the Cancer Therapy & Research Center (CTRC), Finley designed a project to build upon and generate a workload assessment tool for study coordinators.

others. Finley’s tool allowed a coordinator’s workload to be quantified with respect to the complexity of the study and the number of patients who get screened and/or enrolled to it. This means they can track workload and identify when changes in staffing are needed to ensure equitable and manageable workloads for each study coordinator.

Dr. Yun is a recipient of numerous scholarships, including the Fulbright Scholarship during his graduate studies. His research work was selected for oral presentation at the prestigious American Association for Cancer Research Meeting in San Diego. Christina Spencer and Mark Finley

The world of the study coordinator at the CTRC revolves around patient accrual numbers and clinical protocols. Some protocols are more complex than

As a graduate student, he contributed to several publications both as a first author and a co-author. Dr. Yun is currently pursuing his postdoctoral training in the Department of Pediatric Oncology, DanaFarber Cancer Institute, Harvard Medical School, studying epigenetic regulation of carcinogenesis.

Cancer Therapy & Research Center

n

Annual Report 2016 n

11


LOCAL TEENAGER EARNS CTRC DISTINGUISHED SCIENCE AWARD

MAJOR GRANT PROVIDES HUSTON-TILLOTSON STUDENTS EXPERIENCE IN PROSTATE CANCER RESEARCH Robin Leach, Ph.D., director of Scientific Development at the Cancer Therapy & Research Center (CTRC), was recently awarded a Department of Defense (DOD) grant that is a collaborative effort between The University of Texas Health Science Center at San Antonio and Huston-Tillotson University (HTU). This collaboration offers students at HTU the opportunity to participate in an exciting 10-week summer research internship program at the CTRC, a National Cancer Institute-Designated Cancer Center, and participate in state-of-the-art prostate cancer research in many focus areas, including biomarkers, genetics, tumor biology, therapy and imaging. Dr. Leach, professor of cell systems and anatomy at the Health Science Center, said one goal of this program is to help encourage students to learn about the graduate school experience and to equip them with skills to undertake careers in biomedical research focused on prostate cancer.

Nia Clements (left), Diane Clements, Rose Perez (director of the Alamo Regional Science and Engineering Fair), and Dr. Ian Thompson visit after the student’s presentation at the CTRC.

This unique program matches each undergraduate trainee from HTU with a Health Science Center cancer researcher. Participants will engage in research as part of an ongoing cancer research project, attend seminars, actively participate in a student journal club, and tour various research divisions around the university.

Nia Clements, a 16-year-old student at Keystone School in San Antonio, was the recipient of the CTRC Distinguished Science Award at last year’s Alamo Regional Science & Engineering Fair for her incredible research into curing gastrointestinal cancer with sandalwood oil. From the regional fair, Clements went on to win fourth place at Intel International Science and Engineering Fair (ISEF) this spring. She also was one of 140 students invited to participate in the 2016 White House Science Fair. While there, Vice President Joe Biden took a keen interest in her research. Bill Nye, known as Bill Nye the Science Guy, will include Clements’ project in an upcoming documentary. Clements presented her research to CTRC doctors, nurses and scientists on June 30. Those attending were enthralled with her work, and many asked robust questions about her findings. There also were some job offers for this bright young student with a promising future!

12

n

Cancer Therapy & Research Center

n

Annual Report 2016

With funding from the U.S. Department of Defense, undergraduate students from HustonTillotson University in Austin participated in a 10-week summer research internship program at the CTRC.


CTRC Celebrates 25 Years with Esteemed Designation

2

016 marks the 25th anniversary of the Cancer Therapy & Research Center (CTRC) as a National Cancer Institute-Designated Cancer Center.

As we celebrate 25 years of cutting edge scientific discoveries, 25 years of providing patients with the newest and most innovative cancer treatments, 25 years of providing our community cancer prevention services, and 25 years of making lives better, we reflect on our past. We recall the early 1980s when a group of physicians – Drs. Charles Coltman, Kent Osborne, Bill McGuire and Dan Von Hoff from the UT Health Science Center San Antonio – began a decadelong effort to seek a prestigious Cancer Center Support Grant from the National Cancer Institute (NCI). Ten years later, funded in part by the CTRC, these same four professors submitted a joint-venture application with the CTRC and UT Health Science Center as partners. The first NCI designation was received for the jointinstitutional cancer center under its first name: the Institute for Cancer Research and Care (ICRC) in 1991. In April 1993, the name was changed to the San Antonio Cancer Institute or SACI. The NCI designation was renewed in 1996 with the additional designation as a Comprehensive Cancer Center, becoming only the second institution in Texas, along with The University of Texas MD Anderson Cancer Center in Houston to be so designated. The comprehensive designation indicated a stronger and more broad-based research component, as well as attention to outreach, education and prevention.

prevention, tumor-suppressor genes, cancer therapies, cancer metastasis and molecular genetics. In June 2002, the center lost its Comprehensive Cancer Center status due to weaknesses in the areas of prevention and education but retained its NCI clinical cancer center designation. As a result, the CTRC and UT Health Science Center began to re-examine their relationship in the San Antonio Cancer Institute. The resulting new agreement led to the UT Health Science Center becoming the home institution for the Cancer Center Support Grant. On Dec. 17, 2007, CTRC and the UT Health Science Center announced a merger that made the cancer center part of the Health Science Center, and the CTRC as we know it today was born. Today, the CTRC is again in a period of significant growth. The NCI designation was renewed in 2014 for five full years. More than 80 full members of the cancer center receive more than $35 million each year in extramural cancer-related funding. More than 3,000 new cancer patients are seen each year at CTRC with more than 1,500 patients enrolling in clinical trials each year. CTRC is a national leader in the study of cancer in the Hispanic population. We can only imagine what the next 25 years will bring through our collaboration with MD Anderson, a fellow UT System entity. By partnering together, the CTRC and MD Anderson can take cancer care and clinical trials to an unprecedented level for the benefit of those in Texas and around the country. By pooling our incredible resources, research and expertise, the sky truly will be the limit.

SACI continued to grow and eventually included six research programs by the year 2000. These included investigations into breast cancer, cancer

Cancer Therapy & Research Center

n

Annual Report 2016 n

13


patient care 14

n

Cancer Therapy & Research Center

n

Annual Report 2016


A Turn for the Better

T

hroughout his life, retired Marine Col. Harvey Crouch has found a silver lining at every turn, achieving goals far beyond most people.

Commissioned a second lieutenant in 1963, he received his Navy Wings in July 1964 in Kingsville, Texas. While serving two tours in Vietnam, he flew 411 combat missions in the A-4 Skyhawk. Crouch was awarded the Air Medal (an astonishing 26 awards), the Distinguished Flying Cross, and three Legion of Merit awards. He retired from the Marine Corps in 1993 after serving as the commanding officer of the Marine Aviation Support Group in Corpus Christi. Three years later, in 1996, with a diagnosis of prostate cancer, he underwent his first surgery by Dr. Ian Thompson at Brooke Army Medical Center. After his treatment, he continued running, boating, mountain climbing, and summiting Mount Shasta and Mount Hood. With a cancer recurrence in 2006, he underwent a second, major cancer surgery by physicians at the Cancer Therapy & Research Center (CTRC) in San Antonio, but again he didn’t slow down at all. He subsequently climbed Mount Whitney and ran a half-marathon. He took up woodturning in 2008, a hobby that has turned into an artistic endeavor with many intricate pieces that comprise hundreds of individual wood components. These pieces of art have won not only local but also national awards. For Crouch and his wife, Dianne, who now reside on North Padre Island, no challenges have prevented them from enjoying a full and happy life.

(Left) Harvey Crouch creates pieces through the special art of woodturning. (Right) Photos depict Crouch’s military career and active lifestyle.

Cancer Therapy & Research Center

n

Annual Report 2016 n

15


Adding to the arsenal

Battling women’s cancer recurrence followed by three cycles of intravenous chemotherapy. She was cancer free at the end of treatment. The majority of women with ovarian, primary peritoneal or fallopian tube cancer are diagnosed with advanced disease because there is no screening test for these cancers, and most women are asymptomatic until they present with metastatic disease in other sites.

J

uana Hernandez was 47 when first diagnosed with Stage IIIC Patient Juana Hernandez (left) visits with gynecologic oncologist primary peritoneal carcinoma, Georgia McCann, M.D. a cancer that behaves much like including part of her colon. Despite a setback ovarian cancer. Hernandez was of a serious bacterial infection, Hernandez uninsured at the time of her diagnosis. Prior went on to recover well from surgery. She to being evaluated at University Hospital, had intraperitoneal chemotherapy, where she spent nearly two weeks in another local chemotherapy is administered directly hospital but was denied treatment. into the abdominal cavity. This type of chemotherapy can be associated with As expected, she and her family were anxious significant toxicity and can be very hard about the diagnosis and wanted to start on the patient, but it has increased survival treatment as soon as possible. With the help of for some women with ovarian, primary social workers and case managers, the Cancer peritoneal or fallopian tube cancer. Therapy & Research Center (CTRC) was able to help Hernandez establish medical coverage. With careful oversight and excellent nursing, Hernandez successfully completed three In October 2013, she underwent an extensive cytoreductive surgery to remove all visible cancer, cycles of intraperitoneal chemotherapy

16

n

Cancer Therapy & Research Center

n

Annual Report 2016

Similarly, most women’s cancer will return after primary treatment. Unfortunately, Hernandez has experienced two recurrences since she completed therapy. Fortunately, her response to treatment for recurrence has been excellent each time. She is currently receiving weekly chemotherapy with the addition of the anti-angiogenesis agent to help prevent the growth of new blood vessels to feed cancer. Although she remains on treatment today, she has no evidence of cancer. She lives as normal a life as possible and enjoys spending time with her family. With the availability of poly (ADP-ribose) polymerase (PARP) inhibitors, which is a substance that blocks PARP enzymes in cancer cells so they can’t repair their damaged DNA, through clinical trials at the CTRC, Hernandez has many more options for treatment if her cancer recurs. Today, women with ovarian cancer can sometimes live up to 10 years after their initial diagnosis, a number that is staggering for a cancer historically associated with a very poor prognosis. Investigators at CTRC are working every day to help patients live longer!


Cancer Genetics and High-Risk Screening Clinic Juana Hernandez received genetic counseling through the cancer genetics screening program at the Cancer Therapy & Research Center (CTRC). While she does not carry the BRCA mutation, which increases a woman’s risk of breast and ovarian cancer, having this information is powerful for patients as there are steps they and their family members can take to significantly decrease their risk of developing these cancers. The Cancer Genetics and High-Risk Screening Clinic at the CTRC provides patients with comprehensive cancer risk assessment. The assessment helps identify patients who may have hereditary cancer syndromes. It also allows CTRC counselors to educate patients and loved ones, coordinate genetic testing for other family members, and interpret test results for patients and their medical providers. Medical interventions to improve outcomes will be recommended. For more information or an appointment, call 210-450-GENE (4363) or email CTRCReferral@uthscsa.edu.

Preschool teacher Mary Lynn Hauser (left) is cared for by former student Kate Lathrop, M.D., breast oncologist.

Teacher and student reunite through spirit of giving

A

s a preschool teacher for more than 35 years, Mary Lynn Hauser has touched the lives of multiple generations of children.

One of those former students is now caring for Hauser as she battles breast cancer. Kate Lathrop, M.D., breast oncologist at the Cancer Therapy & Research Center (CTRC), is by her former teacher’s side during her treatment at the CTRC. Dr. Lathrop said she is honored to provide medical care for Hauser, whose class she recalls fondly. “My most favorite thing about Ms. Mary Lynn’s class was going out for trips around the block of our church preschool. She had a long, thick twine rope with knots tied at evenly spaced intervals of which my 3-year-old fingers barely reached around. We would all line up and grab onto our chosen knot and off we went with her at the lead. “There was never an obvious agenda or goal to these outings. It was simply to go outside and see what

we could find. We talked to postmen, counted butterflies, collected samples of leaves, and spotted ideas for later art creations. One hand on a knot at all times and one hand free to explore,” she said. During her first year of training for her hematology and oncology fellowship, Dr. Lathrop said she truly appreciated the value of such a wonderful teacher. “That year was the toughest of all my years of medical training. It required long hours at the hospital and many weekends away from my family. But, that year was made so much better knowing that my daughter was in the loving care of one of my favorite teachers, Ms. Mary Lynn,” she said. “These first two years of my career as a breast oncologist have provided many amazing and novel opportunities. There have been many times when I have reached out for this figurative rope, grabbed onto my knot, and joined the group in an exercise of exploration. It is this spirit of exploration and feeling of assurance that good things will come from your efforts that is her lasting message,” she added.

Cancer Therapy & Research Center

n

Annual Report 2016 n

17


SKIN CANCER: A Clear Margin for Success Dermatology patient benefits from specialized procedure

S

outh Texas is called the hotbed of skin cancer for a reason. In June, there are nearly 280 hours of sunshine and a peak of 308 hours in August. That’s a lot of UV radiation exposure.

Skin cancer is the most common type of cancer in the United States with more than 2 million Americans diagnosed each year. While melanoma isn’t as common, accounting for only 2 percent of all skin cancers, it is the most deadly. There will be an estimated 73,870 new cases of melanoma diagnosed this year, and nearly 10,000 people were expected to die in 2015 from the cancer, according to the American Cancer Society. While it’s easy to think about getting too much sun exposure from direct, bright sunlight, UV rays can affect you even on cloudy and hazy days and can be reflected off of surfaces such as water, snow, sand and cement. UV radiation exposure is responsible for more than 90 percent of melanoma skin cancers. And it only takes five or more sunburns in a lifetime to double your risk for getting melanoma. As Vineet Mishra, M.D., director of Mohs Surgery and Procedural Dermatology at the Cancer Therapy & Research Center (CTRC), points out, “In South Texas, we must remember that the sun and skin cancer are equal opportunists. There is a misconception that skin cancer only affects certain races. In fact, it affects people of all races, all ages and both genders. It’s a major cause of concern.” According to Dr. Mishra, it is a myth that Hispanics, the majority ethnic group in South Texas, are not affected by UV rays because of their darker pigmentation. Despite the ease at which they tan rather than burn, it is urgent that Hispanics use sun protection. Paloma Leal, a patient of Dr. Mishra, agrees. She has been rigorously treated for almost one year after having surgery to remove a cancerous mole from her lip. “I consulted with a dermatology doctor in Mexico, and he told me that it was herpes, a virus, and would never go away. At that time, I didn’t like his answer,” Leal said.

18

n

Cancer Therapy & Research Center

n

Annual Report 2016

When she returned to San Antonio, she sought a second opinion at the CTRC. After a biopsy, she was diagnosed with the most common type of skin cancer which is basal cell. Dr. Mishra removed the lip cancer over three different stages and grafted tissue from below her ear. She has had more than 20 visits but slowly the scar is disappearing. Leal believes the cancer happened because she didn’t take care of her skin. “I have never used sun block,” she said. “I would recommend that if you see any small spot on your skin immediately go to a dermatologist because this could cause death.” In addition to the basal cell carcinoma that Leal endured, there are other types of skin cancer. Squamous cell and melanoma are the most dangerous but less common. Even though melanoma is not common, it affects one out of 50 people in the U.S. If it’s not detected in time, these cutaneous cancers can disseminate into other tissue or organs and could be fatal.


TYPES OF SKIN CANCER • Basal cell carcinoma is the most common type of skin cancer. It most frequently affects people with fair skin. • Squamous cell carcinoma is the second most common type of skin cancer, and most often affects those with fair skin. • Melanoma is the deadliest type of skin cancer and often develops as an asymmetric, irregularly bordered, multi-colored, large and evolving dark spot.

WAYS TO PREVENT SKIN CANCER The Centers for Disease Control and Prevention suggests easy options for protection from UV radiation: Dermatologist Vineet Mishra, M.D., (left) examines patient Paloma Leal.

• Stay in the shade, especially at peak sun hours during the middle of the day. • Cover your arms and legs with clothing.

CTRC skin cancer experts, such as Dr. Mishra, are ready to help. Mohs is a micrographic surgery that allows physicians to remove a tumor while leaving the surrounding healthy tissue unharmed. Dr. Mishra is one of nearly 1,200 fellowshiptrained Mohs surgeons in the U.S. Mohs surgery is the most effective treatment for most types of skin cancer and has the highest cure rate. In skin cancer, a small lesion can conceal a dangerous mass with roots underneath, similar to the potential threat of an iceberg – you never know what’s lurking beneath the surface. With Mohs surgery, skin cancer is removed in layers. After each layer is removed, it is examined under a microscope. The process continues until healthy tissue around the cancer, or a clear margin, is reached.

• Wear hats, especially those with wide brims that cover your entire face, ears and neck. • Wear large sunglasses that block out both UVA and UVB rays. • Use sunscreen with an SPF of 50 or higher, and one that offers both UVA and UVB protection. • Don’t use tanning beds or other indoor tanning facilities.


ONE GIANT LEAP AGAINST CANCER I

n President Barack Obama’s final state of the union address he tasked Vice President Joe Biden with leading a new national effort to end cancer.

On June 29, Vice President Biden convened the National Cancer Moonshot Summit, a first-of-its-kind summit with the goal of making a decade’s worth of progress in preventing, diagnosing and treating cancer in just five years and ultimately striving for a cure. The Moonshot Summit provided a unique venue for reaching Americans across the country and bringing together patient advocates, health care providers, biomedical researchers, technological innovators, industry leaders and others to form collaborations in support of the national battle against cancer. The initiative involves every sector of society — government agencies comprise the Cancer Moonshot Task Force; scientists, academics and private researchers make up a blue ribbon panel; philanthropists, patients, foundations and the private sector contribute in large and small ways. Everyone has a role to play. The White House announced a $195 million investment at the National Institutes of Health (NIH) in fiscal year 2016 as part of a proposed nearly $1 billion budget initiative for the Cancer Moonshot.

The Cancer Therapy & Research Center (CTRC) hosted a regional Cancer Moonshot Summit on June 29 while 270 similar summits were simultaneously held around the country.

research 20

n

Cancer Therapy & Research Center

n

Annual Report 2016

At the CTRC, participants were addressed via teleconference by Vice President Biden before they began roundtable discussions, which covered topics such as listening to patient concerns, helping more patients access care, identifying exemplary models for assisting patients with navigating treatment, and financing care for low-income patients.


CPRIT AWARDS $10.9 MILLION FOR PEDIATRIC CANCER RESEARCH The Cancer Prevention & Research Institute (CPRIT) awarded $10.9 million for core resources that will support the Cancer Therapy & Research Center’s (CTRC) cancer research enterprise.

Cancer survivors, patients, physicians, researchers, advocates and philanthropists participated in the June 29 regional Cancer Moonshot Summit, located at and hosted by the CTRC.

A summary of the main points from the CTRC summit were compiled and sent to the National Cancer Institute’s National Cancer Advisory Board for review and prioritization. Ian M. Thompson, M.D., CTRC director, told summit participants, “This is similar to when President (John F.) Kennedy announced in 1961 that we would put a man on the moon in less than a decade.” Instead of landing a man on the moon, the goal of the Cancer Moonshot is to accelerate research toward a cure for cancer so the nation will achieve in five years what would ordinarily take 10 years, he said. “We are hoping to look outside the box at innovation. Millions of people and their families are depending on you,” Dr. Thompson told local attendees.

The funding includes: • $5 million for the Greehey Children’s Cancer Research Institute’s (GCCRI) Texas Pediatric Patient Derived Xenograft (PDX) Facility, led by Peter Houghton, Ph.D., director of the GCCRI. This core establishes a coordinated effort between the GCCRI and the UT Southwestern Medical Center to develop new animal models that can be used to test new therapies in children whose cancer has relapsed or who are from minority groups that have typically not responded well to current treatments. The models will be developed using state-of-the-art approaches and will be made available to pediatric researchers in Texas and across the U.S. • $3.6 million to update and expand existing infrastructure in the CTRC Next Generation Sequencing Shared Resource to establish the Cancer Genome Sequencing and Computational Core. This award to Yidong Chen, Ph.D., will provide the South Texas research community with access to cutting edge genomic analyses to support their research. Dr. Chen serves as director of the Division of Computational Biology & Bioinformatics at the GCCRI and as co-director of the CTRC Next Generation Sequencing Bioinformatics Shared Resource. • $2 million for the recruitment of Myron Ignatius, Ph.D., from Massachusetts General Hospital/Harvard Medical School. Dr. Ignatius has developed a genetic model of a type of soft tissue cancer called embryonal rhabdomyosarcoma that generally occurs in children. • $200,000 to develop a strategy to target EWS-FLl-1, a fusion oncoprotein that causes Ewing sarcoma, a bone and soft tissue cancer in children. The grant was awarded to Yuzuru Shiio, M.D., Ph.D., associate professor of biochemistry at the UT Health Science Center San Antonio. JOINT CIDD PROGRAM RECEIVES $4.6 MILLION

In addition, CPRIT awarded a $4.6 million grant to the Center for Innovative Drug Discovery (CIDD), a joint program of the Health Science Center and its sister institution, The University of Texas at San Antonio (UTSA). This award to Stanton McHardy, Ph.D., of UTSA, CIDD co-director and a CTRC member, will be shared by the two institutions. The CIDD, whose Health Science Center component is directed by Bruce Nicholson, Ph.D., CIDD founder/co-director, was founded to facilitate the translation of home-grown discoveries into novel cancer treatments. The CIDD is focused not only on the discovery of new molecules but also on the design and creation of molecules that can be engineered to aggressively target cancers. Cancer Therapy & Research Center

n

Annual Report 2016 n

21


DISCOVERY OF THE YEAR

H

ow does a protein called connexin put the clamps on cancer? Jean Jiang, Ph.D., and her colleagues have an explanation.

Gap junctions are connections between cells that allow various molecules and ions to pass freely. Gap junctions and the proteins that form them, called connexins, are essential in regulating many cellular processes, including cell growth. The dysregulation of connexins have been shown to have a huge impact on tumorigenesis and disease development. Many clinical studies suggest a loss or reduced expression of connexins in tumor tissues. It has been known for a while that connexin expression slows cell proliferation by increasing the production of inhibitors for molecules called cyclin-dependent kinases (CDKs). However, how this critical process operated remained unknown until Dr. Jiang and her team made an important discovery. Dr. Jiang, professor of biochemistry at the UT Health Science Center San Antonio, found that connexin tethers itself to a cell-proliferating molecule called Skp2. This prevents the Skp2 from traveling to the cell nucleus to promote more cell growth, she said. The majority of cells in the body have connexin proteins, but primary tumors have very low amounts. “This is because the presence of connexins suppresses primary tumor growth,” said Dr. Jiang, a member of the Cancer Development and Progression Program at the Cancer Therapy & Research Center (CTRC).

22

n

Cancer Therapy & Research Center

n

Groundbreaking finding can lead to tricking, slowing cancer cells

Dr. Jiang and her team study the eye lens, which is rich in connexin proteins, as a model system to understand how connexin functions in cells throughout the body. “If there is a way to amplify the presence of connexin, then there can be a way to suppress the cell proliferation, for example in cancer,” Dr. Jiang said. In the future, cancer therapies could potentially be based on connexin molecules, the study suggests. Dr. Jiang’s groundbreaking finding is conceptually innovative and highly translatable to the clinic. It offers a previously unappreciated way to trick tumor cells into making more of their own endogenous CDK inhibitors, slowing their growth. There is a renewed interest in targeting CDK activity as an anticancer therapy. Palbociclib, the first FDA-approved drug of this type, exhibits significant clinical efficacy for treating postmenopausal breast cancer. Several additional CDK-inhibiting compounds are in clinical trials. This study, published in the journal Developmental Cell, was selected as the 2016 CTRC Discovery of the Year. Dr. Jiang’s research is funded by a fiveyear, $1.6 million grant from the National Eye Institute of the U.S. National Institutes of Health.

Annual Report 2016

Jean Jiang, Ph.D., (left) accepts the Discovery of the Year Award from Ian M. Thompson, Jr., M.D., CTRC director.


Historic clinical trial for brain tumor result of large-scale collaboration

A

ndrew Brenner, M.D., Ph.D., who holds the S&B Kolitz/CTRC-Zachry Endowed Chair in Neuro-Oncology Research, was recently selected as the 2016 Clinical Investigator of the Year at the Cancer Therapy & Research Center (CTRC) for his passionate commitment to early phase experimental therapeutics and translational research in one of the most challenging areas of all of solid tumor oncology – brain tumors.

CLINICAL INVESTIGATOR OF THE YEAR

Each success led to more work at higher levels, until Dr. Brenner was setting up the collaboration with the nanotechnology characterization lab at the National Cancer Institute. He sent the national lab the procedures and samples and they analyzed them. The results were solid, and led to an investigational new drug application with the FDA.

Andrew Brenner, M.D., Ph.D., (left) is presented the Clinical Investigator of the Year Award by Dr. Thompson.

Separately, the CTRC Foundation collaborated with the UT Health Science Center to create a company, NanoTx Therapeutics, which could access funding to push the research forward faster than the academic His work is on glioblastomas, the deadliest of brain machine normally does. tumors, and he has found a new way to target them Working with NanoTx, with nanotechnology. Dr. Brenner, a CTRC neuroDr. Brenner wrote oncologist, is leading the first trial to use this new business and scientific technology in patients. proposals, gaining a Nanotechnology involves tiny radioactive fat $2 million grant from particles, only 100 nanometers across, inserted by the Cancer Prevention the thinnest of catheters directly into a tumor, where and Research Institute they remain, radiating only a tiny distance, affecting of Texas. only the tumor. The concept was developed at the Dr. Brenner has shown UT Health Science Center for use in head and neck that Phase I trials in neurocancers. But Dr. Brenner had a different vision. oncology can be done and “I thought it made sense to use it in brain cancer done extremely well. He has first,” he said. “The skull is a rigid structure” and the worked to eliminate barriers tissue inside is much less varied, he said, whereas in for these trials and has built this the neck and other parts of the head there are many program from scratch. different kinds of tissue and lots of moving parts. Dr. Brenner has led an exceptional effort to provide better treatment for brain tumor patients using large-scale collaboration requiring intense cooperation between medical oncology teams, neurosurgery teams, clinical trials teams and translational research teams.

Cancer Therapy & Research Center

n

Annual Report 2016 n

23


CTRC investigators working on SPORE grants

T

he National Cancer Institute’s Translational Research Program is home of the SPOREs – the Specialized Programs of Research Excellence – a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research.

SPORE grants involve both basic and clinical/applied scientists working together. SPORE projects result in new and diverse approaches to the prevention, early detection, diagnosis and treatment of human cancers. SPORE grants from the NCI are some of the largest and most prestigious methods by which the NCI stimulates innovative science focused on cancer. Cancer Therapy & Research Center (CTRC) investigators are working toward the submission of two SPORE grants – one in prostate cancer and one in breast cancer. PROSTATE SPORE Over the past 30 years, physicians and scientists at the CTRC have helped design and lead some of the most important studies in prostate cancer, including: The Prostate Cancer Prevention Trial – a study of 18,882 men that demonstrated almost one-third of prostate cancers can be prevented with the drug finasteride. The Selenium and Vitamin E Cancer Prevention Trial – a study of more than 35,000 men that showed Vitamin E supplementation increases the risk of prostate cancer by 17 percent. A NCI-sponsored study – this study demonstrated a significant reduction in death from prostate cancer when radiation is administered after surgery for high risk cancer. The PCPT Risk Calculator – this is the most widely used tool in the world for the assessment of a man’s risk of prostate cancer. The PASS Active Surveillance Clinical Trial – this study confirmed the value of active surveillance (instead of surgery or radiation) for men with low-risk prostate cancer. Most prostate cancer SPOREs in the United States have a primary focus of developing new treatments for patients with advanced prostate cancer. A unique focus of the CTRC Prostate Cancer SPORE will be on improving early detection and prevention of prostate cancer. It has long been acknowledged that early detection and prevention of prostate cancer has the potential and track record of saving far more lives than the treatment of established disease as well as being a far more cost-effective way to prevent suffering from cancer. The CTRC has 34 physicians and scientists currently working on a broad range of prostate cancer research. Highlights include:


Robin Leach, Ph.D., professor of cell systems & anatomy and urology, and CTRC’s director of Scientific Development – Dr. Leach has identified genetic variants, present in 10 percent of the population, that lead to low levels of PSA in men with cancer. These variants may delay the detection of potentially lethal prostate cancers. She is working closely with Dr. Ian Thompson on this project. Michael Liss, M.D., assistant professor of urology – Dr. Liss is implementing a new technique for performing prostate MRI that rapidly identifies cancers, allowing earlier and more precise diagnosis. John DiGiovanni, Ph.D., member of the Population Sciences and Cancer Prevention Program of the CTRC and professor at UT Austin – Dr. DiGiovanni has discovered that fat cells around the prostate may contribute to prostate cancer development and growth. He is working with Jill Hamilton-Reeves, Ph.D., a collaborator from the University of Kansas, as well as Rob Svatek, M.D., a CTRC urologic oncologist. Denise O’Keefe, Ph.D., associate professor of urology – Dr. O’Keefe is examining the role of folate in modifying prostate cancer incidence and progression. She is collaborating with Sarah Ullevig, Ph.D., from UTSA and Dr. Liss. David Morilak, Ph.D., professor of pharmacology – Dr. Morilak has identified a novel medication that may prevent development of cognitive (ability to think and perform day-to-day decision-making) changes that are seen in men with prostate cancer treated with hormone therapy. He is working with Drs. Javier Hernandez and A. Campbell Sullivan to design a clinical trial to test this. Ian M. Thompson, Jr., M.D., director of the CTRC and professor of urology – Dr. Thompson leads the GU Committee of SWOG, the largest group of prostate cancer investigators conducting NCI Clinical Trials in the United States. Multiple large, practice-changing clinical trials are led by Dr. Thompson and his colleagues. He is leading the prostate SPORE effort.

BREAST SPORE CTRC has a long history of excellence in the field of breast cancer research. That continues today with a new group of investigators who are reaching out beyond the walls of CTRC and the city limits of San Antonio to form a unique partnership with investigators at Houston Methodist Hospital, led by Jenny Chang, M.D. The Breast SPORE initiative also has a large number of investigators working to develop new and better treatments for breast cancer. The CTRC has 26 physicians and scientists currently working on a broad range of breast cancer research. Highlights include: LuZhe Sun, Ph.D., professor of cell systems & anatomy and the CTRC’s associate director for Translational Research – Dr. Sun’s ongoing research projects include the investigation of how aging, obesity, radiation, and xenoestrogens may induce a tumorigenic phenotype of mammary stem cells as well as the development of therapeutic approaches for the prevention of agingassociated breast cancer. Virginia Kaklamani, M.D., professor of medicine, Division of Medical Oncology and CTRC’s associate director for Clinical Research – Dr. Kaklamani is an expert in the care and management of breast cancer patients as well as in the genetics of breast cancer. She is working on a variety of projects all aimed at better care and treatment for our breast cancer patients through state-of-the-art research. Ismael Jatoi, M.D., professor of surgical oncology – Dr. Jatoi has a longstanding interest in the treatment of breast cancer and the management of women who are at increased risk for breast cancer. Tyler Curiel, M.D., M.P.H., professor of medicine in the Division of Medical Oncology and co-leader of the Cancer Development and Progression Program at CTRC – Dr. Curiel is an internationally recognized immunologist working to harness the specificity and

sensitivity of the patient’s immune system to eradicate breast cancer Rong Li, Ph.D., professor of molecular medicine and co-leader of the Cancer Development and Progression Program at CTRC – Dr. Li made the pioneering discovery of a molecular switch that turns on the antitumor activity of the estrogen receptor beta (ERβ). His laboratory is now working on using this molecular switch to inhibit the growth of triple negative breast cancer and circumvent hormonal resistance of ERβpositive breast cancer. Susan Mooberry, Ph.D., professor of pharmacology and co-leader of the Experimental and Developmental Therapeutics Program at CTRC – Dr. Mooberry identified a new natural compound that shows great potential against triple negative breast cancer and provides clues on how best to treat a subset of these tumors that are androgen receptor positive. Manjeet Rao, Ph.D., associate professor of molecular medicine – Dr. Rao has shown that nitric oxide signaling is associated with poor prognosis in estrogen-receptor negative breast cancer and may induce metastasis. He is working on a new agent that when combined with chemotherapy will improve its efficacy.

Dr. Tyler Curiel


POETIC JUSTICE

Fighting the Toughest Pediatric Cancers

A

clinical trial of a new immunotherapy agent for children and young adults who do not respond well to traditional therapy or whose cancer returns is being offered at the UT Health Science Center San Antonio – the first study site in the U.S. to offer the trial. The study, led locally by Anne-Marie Langevin, M.D., evaluates the drug atezolizumab, which has shown promising results in adults. It is being offered to children ages 2 to 17 and young adults up to age 30 who have pediatric cancers. The focus is on solid tumors and two types of lymphomas, Hodgkin lymphoma and nonHodgkin lymphoma. In 2015, the university joined the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC), a group of 11 academic medical centers in North America whose pediatric oncology studies focus on the biologic basis for anti-cancer therapy, and investigate new agents and novel combinations of therapies early in clinical development. “We joined POETIC to offer children the newest therapies that are not available yet at other centers,” said Steven D. Weitman, M.D., Ph.D., principal investigator and director of the Institute for Drug Development at the Cancer Therapy & Research Center (CTRC). “If we were not involved in this, our patients would have to wait

26

n

Cancer Therapy & Research Center

n

years before these treatments would be available commercially to the public.” The first trial of the drug atezolizumab has already proved promising. Based on results from several clinical trials in adults, the U.S. Food and Drug Administration in February granted Breakthrough Therapy Designation for atezolizumab for treating non-small cell lung cancer in adults. Atezolizumab also has shown good results against a type of bladder cancer called metastatic urothelial carcinoma. The drug is being tested with numerous other types of cancer in adults. “Even though we’ve had some great advances over the past 40 years in treating cancer with chemotherapy, radiation and surgery, there have been few new treatment options for children and young adults who do not respond well to traditional therapy or whose cancer relapses. This is our sickest group of patients because the standard therapies no longer work,” said Dr. Langevin, professor of pediatric hematology/ oncology at the Health Science Center. “Atezolizumab uses the body’s own immune system to fight the cancer. The new trial will look at how pediatric tumors and children’s developing bodies react to the new medication,” she said. The study eventually will be offered at 50 study sites in Europe and the United States.

Annual Report 2016

Dr. Anne-Marie Langevin


CTRC COUNCIL SUPPORTS INNOVATIVE PILOT STUDY

PRESIDENTIAL JUNIOR RESEARCH SCHOLAR STUDYING CANCER IN HISPANIC POPULATION

L

H

elen Parsons, Ph.D., M.P.H., assistant professor in the Department of Epidemiology and Biostatistics at the UT Health Science Center San Antonio, was recently named a Presidential Junior Research Scholar. Dr. Parsons, who came to the Health Science Center and the Cancer Therapy & Research Center (CTRC) from the National Cancer Institute, is focused on examining how health policy and quality guidelines affect appropriate treatment and outcomes for cancer.

Dr. Helen Parsons

Amelie Ramirez, Dr.P.H., M.P.H., associate director for Population Science at the CTRC, noted that Dr. Parsons’ work in cancer and health services research has helped to shift the dialogue among vulnerable cancer survivors. She has focused her research on examining how health policy and quality guidelines affect appropriate treatment and outcomes for cancer, and has made major contributions to the underlying theory behind these recommendations for cancer survivors. In the process, she has developed a national reputation for her contributions to cancer health policy. A shining example of this work is her recent paper with Kate Lathrop, M.D., and Anand Karnad, M.D., of the CTRC’s Division of Hematology/Oncology, on breast cancer treatment delays in Hispanic women. Evidence from several large national studies has shown that there is a treatment delay in Hispanic women diagnosed with breast cancer. Drs. Parsons, Lathrop and Karnad conducted a study at the CTRC to determine if this was the case in a community with a majority Hispanic population. Importantly, in contrast to the results obtained nationwide, they found that at the CTRC there was no difference among the ethnic groups for either time from mammography to biopsy or biopsy to treatment. This important work suggests that the delay in treatment by Hispanic women nationwide is not intrinsic to the group and that initiatives can be undertaken nationally to ensure there is no delay in treatment in the future.

Dr. Deva Mahalingam

iver cancer cases and deaths due to liver cancer are growing at an alarming rate in the United States. The situation is even more critical in South Texas where the incidence of liver cancer is about 50 percent higher than the rest of Texas and the nation.

Even more alarming is that liver cancer rates are twice as high in South Texas Hispanics than in their non-Hispanic white counterparts. As a result, the Cancer Therapy & Research Center (CTRC) has focused considerable effort on combating liver cancer. Deva Mahalingam, M.D., associate professor of medical oncology at the CTRC, is leading a pilot study supported by the CTRC Council aimed at increasing the survival of patients with liver cancer. Most patients with liver cancer are not diagnosed until the disease is already in advanced stages and treatment options currently available do not offer much hope of cure. In fact, there is only one systemic therapy, a drug called sorafenib, which is currently approved for patients with advanced liver cancer and only modestly improves survival. This means that many tumors likely have become resistant to sorafenib. Dr. Mahalingam and his colleagues believe the therapy induces a process called autophagy which allows the cancer cells to survive. Autophagy is one of the ways cells clean up after themselves. It is a natural way for the cell to very orderly degrade and recycle parts of the cell to balance energy and is particularly important in times where the cell may not be getting enough nutrients. In cancer cells, this process becomes dysregulated and the cancer cells may depend on the mechanism to survive. Cancer therapeutics may mimic the situation in which cells are nutrient deprived, and autophagy is increased in the cancer cells, leaving the tumor cells resistant to therapy and able to escape cell death. This research team has already seen promising results in pre-clinical laboratory studies looking at combining sorafenib with a drug called hydroxychloroquine or HCQ, which inhibits autophagy. They followed this with studies to show sorafenib and HCQ together were safe in humans. Now, they are taking the next step to treat liver cancer patients at the CTRC with these two drugs. They are confident this combination will be more effective than sorafenib alone and will improve survival in our patients with advanced liver cancer. The study is currently enrolling patients. This is a prime example of how a gift to the CTRC can give hope to the cancer patients of South Texas and change the way cancer is treated.


clinical trials

Clinical trial gives patient hope of longer life with lung cancer

I

t started in mid-April 2015 with a headache. “It felt like a really bad migraine and it was constant, it wouldn’t go away,” said Mona Lisa Mejia, a San Antonio mother of four.

After a week, Mejia went to her physician who diagnosed a sinus infection. But the crushing pain, nausea and weakness only got worse. On May 1, 2015, she could not hold down the medicine her doctor prescribed – or even water.

The CTRC’s Southwest Oncology Group (SWOG) team puts patients in clinical trials from the national group every day.

CTRC Leader in Worldwide Cancer Clinical Trials Network

T

he Cancer Therapy & Research Center (CTRC) is a member of SWOG, formerly known as Southwest Oncology Group, a worldwide network of researchers that design and conduct cancer clinical trials. The group’s goal is to change medicine practice so it improves the lives of people with cancer. SWOG, which is celebrating its 60th anniversary in 2016, is one of the largest organizations conducting cancer clinical trials funded by the National Cancer Institute. CTRC has a long history of leading these trials as well as ensuring that patients from San Antonio and South Texas have the opportunity to participate in these critical, practice-changing studies. These studies involve not only medical

28

n

Cancer Therapy & Research Center

n

therapies but new forms of radiation and even innovative surgical treatments. The CTRC is proud to be ranked sixth (out of 990 institutions) for enrollments to SWOG clinical trials in 2015. Along with patients from CTRC and those from around the U.S. who are the real heroes, the very special research team at CTRC worked tirelessly and enrolled 100 patients in studies in 2015. This broke the previous record of 77 patients in 2012. The CTRC is on track to do even better this coming year and is steadily working its way to No. 1 on the list. We are all so proud of their achievement; through their work, accelerated advancements in cancer cure are possible for our patients!

Annual Report 2016

“It was unbearable,” Mejia said. “I called my husband at work and he came home and took me to the emergency room. By then I could barely walk.” Mejia was diagnosed with Stage 4 lung cancer that had spread to her brain. The diagnosis was a huge blow to the Mejia family, which had lost their baby girl, Emma, six years before to rhabdomyosarcoma when she was only 18 months old. (Rhabdomyosarcoma is generally a children’s cancer that develops in the connective tissues of the body.) “We were so scared because we’d been through this battle with cancer before, but we stuck together. Our family, friends and my husband’s coworkers are very supportive,” she said. Meals began arriving at her home and Mejia’s father stepped in to help with the three children – Henry, 17; Julian, 12; and Hannah, 3 – so Mejia’s husband, Kevynn, could be with her at the hospital. Non-small cell lung cancer is the leading cause of cancerrelated deaths worldwide and results in about 160,000 U.S. deaths each year. About 15 percent of patients with non-small cell lung cancer have a genetic mutation of a protein on the surface of cells called epidermal growth factor receptor (EGFR). EGFR causes normal cells to grow and divide, but some non-small lung cancer cells have too


“There are many types of non-small cell lung cancer. We learned of a clinical trial that compares two treatments for the type of lung cancer Mona has,” Dr. Jeong said. The clinical trial is offered through SWOG, one of several large NCI-funded cancer clinical trial groups to which the CTRC belongs. In the trial, patients are randomly assigned to two groups. One group receives afatinib, an oral medication, while the other group receives an afatinib pill and centuximab intravenously. In several clinical studies, afatinib was shown to block the ability of cancer cells to reproduce and had fewer side effects than chemotherapy, the previous standard treatment. However, after about a year, the cancer cells usually find a way to mutate and begin multiplying again. Dr. Woodong Jeong

much of this protein and it fuels rapid growth of tumors throughout the body. Mejia’s specific type of cancer is called EGFR-mutated non-small cell lung cancer. To treat the lesions in her brain, Mejia was referred to Richard Crownover, M.D., Ph.D., a radiation oncologist with the Cancer Therapy & Research Center (CTRC). “She had multiple tumors growing in the brain that were causing such severe headaches and weakness that she collapsed in the parking lot on the way to her first appointment,” Dr. Crownover said. “This was an emergency. We had Mrs. Mejia begin radiation treatments the same day to begin shrinking the brain tumors.” After two weeks of radiation therapy, Mejia began lung cancer treatment June 1, 2015, with Woodong Jeong, M.D., a CTRC hematologist/oncologist.

In other trials in animals, the combination of centuximab and afatinib was shown to work better than either one alone. Researchers hope the current trial will help decide which treatment works better in humans. So far Mejia has beaten the odds. On June 1, she celebrated her one-year anniversary of cancer survival with a visit to Dr. Jeong. Her tumors have shrunk and are stable. “She is on the right track to have a good result so far,” he said. Although Mejia’s side effects of diarrhea, nausea and fatigue were problematic when she first started taking afatinib, her body has adjusted to them, and her family has adjusted better to her having cancer. “My kids are worried about me, but we continue to have faith in God,” Mejia said. “Our faith has gotten us through all of this and without it I would have lost hope. I prayed and He answered. He sent all of these angels to help me. I am just so grateful.”

CTRC offers large variety of cancer clinical trials in South Texas As an academic institution and one of only four National Cancer Institute-Designated Cancer Centers in Texas, the Cancer Therapy & Research Center (CTRC) offers many opportunities for patients to participate in cancer clinical trials close to home in South Texas. Clinical trials are research studies that explore the newest medical strategies, devices and treatments to determine if they are safe and effective for humans. The results of clinical trials can lead to new standards of care in preventing and treating cancer, and in improving the quality of life for patients. More than 160 clinical trials are open at any one time through the CTRC, with approximately 1,525 patients participating. The trials are funded through a variety of sources, including the National Cancer Institute, pharmaceutical companies and private donors. They include: • Studies initiated by UT Health Science Center physicians and researchers; • New drugs developed by CTRC’s world-renowned Institute for Drug Development; • Studies conducted specifically for South Texas’ Hispanic population, which often doesn’t respond the same way to standard treatment as other population groups; and • Clinical trials conducted by large-scale NCIsponsored clinical trial groups that offer multiinstitutional studies conducted throughout the U.S. or even internationally. For more information about CTRC’s cancer clinical trials, call (210) 450-1000 or visit uthscsa.edu/patient-care/ctrc/clinical-trials


service outreach

CTRC Happily Goes to the

DO

A CTRC patient enjoys visiting with Ollie.

30

n

Cancer Therapy & Research Center

n

Annual Report 2016


S

miles abound when Ollie, Hunter, Lucy or Oliver walk into the treatment rooms at the Cancer Therapy & Research Center (CTRC).

Patients look forward to their visits and many have special relationships with these honored guests. Nurses eagerly anticipate their visits, and one in particular greets them with a special treat. Who are these beloved guests? Ollie, Hunter, Lucy and Oliver are dogs! Their loving and thoughtful humans bring them to the CTRC each week to cheer patients undergoing chemotherapy treatments. These wonderful animals offer love and acceptance to people who are going through a very difficult time.

PAWS for Service volunteers at the CTRC include Christina Tax with Oliver, Vicki Petty with Hunter, Linda Love with Ollie, and Courtney Smith with Lucy.

GS

For a brief moment patients can forget the unwanted battle they are facing and be entertained by these special visitors who don’t know the difference between sick and well.

The animals and their owners are part of PAWS (Pets Are Wonderful Support) for Service, an organization with the goal “to improve human health and well-being by promoting mutually beneficial relationships with animals and using them as examples of God’s unconditional love.” Locally there are 100 (human/dog) teams working throughout the city offering love and understanding to those who need a moment of normalcy in the midst of suffering, fear or loneliness. Hunter’s owner, Vicki Petty, said, “Hunter, Lucy, Oliver, and Ollie are not afraid of cancer. Their eyes see beyond the tubes, the pain, the fear and the frustration to a brighter future or at least a normal one. I personally believe God knew what he was doing when he made a dog man’s best friend. He knew we would need such comfort and companionship in challenging times. It is my greatest privilege to work alongside Hunter and all of the personnel at the CTRC to stand against the soon-to-be-defeated disease known as cancer.” Courtney Smith, who brings Lucy the Goldendoodle, said, “The visits we do at the CTRC and at University Hospital are such a blessing. I always walk away feeling grateful. I have met so many nice people – from the patients, staff, doctors and other volunteers. Lucy loves her visits; she gets excited when I pull out her blue bandana because she knows she is going to `work.’ ” Smith said Lucy pulls her into Brian Allen’s Phase I treatment room as soon as they step off the elevator so she can get the yummy treats he has for her in the cabinet she points to with her nose. CTRC staffer Brian Allen gives treats to the canine volunteers.


Above and Beyond Drew Roy

V

olunteer Drew Roy believes the Cancer Therapy & Research Center (CTRC) chose him rather than the other way around.

His wife, Dianna, has been very involved with the CTRC Council and also serves on the Board of Governors. After listening to her many stories about the CTRC’s focus on patients, innovative drug development programs and excellent treatment facilities, Drew Roy paid an impromptu visit to Mary Jackson, CTRC’s director of Patient and Family Services, and told her he wanted to help in whatever way he could. Jackson was quick to direct him to the information desk, but then she started sending him to help with the inventory in the oncology department. The more people he met, the more eager he was to join the team. Eventually Jackson asked if he would revive the Patient and Family Services’ newsletter, which was a quarterly printed publication. Roy embraced this challenge by researching publications from other cancer treatment facilities. Based on his research, he created an online publication and named it Living Well. With that task well in hand, Jackson then challenged Roy to re-think the services offered at the information desk by working with the employees and volunteers to become more service oriented. Jackson and Roy both realized the need to actively engage those arriving for treatments and to become their advocate while they are here. Roy embraced this task with his usual zeal and know-how and, before long, created an organized schedule of tasks that were needed and trained a now mighty team of more than 50 volunteers – from a mere handful. “One of the joys of volunteering is getting to know the patients. They are going through a tough time, but they are so appreciative of a kind word or deed. I feel very humbled just to be in their presence. They are my heroes,” Roy said.

Finding a Soul Friend

C

ancer survivor Beverley McClure is more than just a good listener. She understands the tribulations of battling the dreaded disease. That’s why patients are eager to tell her their stories. “I had a wonderful conversation with a woman who was headed to hospice. She told her doctors she wasn’t ready to die and asked them to find her a treatment. She’s now in a Phase I trial,” McClure said. “She talked about her life, the things she had done and how she was diagnosed. Her courage was amazing.” McClure volunteers as a soul friend at the Cancer Therapy & Research Center (CTRC). She offers emotional and spiritual support to patients facing the scourge of all illnesses. “I get back so much from the patients,” she said. “It actually feeds my soul to hear their stories. Many are feeling overwhelmed and need some strength. I try to provide that positive connection.” McClure, a retired USAA executive, began her training for the soul friend volunteer position last year. Her role in the corporate world and her subsequent career as an executive coach prepared her for the task. “After 34 years at USAA, I started my own business,” she said. “As an executive coach, listening, being present and asking questions caused people to look inward. Those same skills help me today.” McClure is no stranger to the CTRC. She serves on the CTRC Council’s Board of Trustees. “I love my work with the council, but I wanted to work directly with patients,” she said. “I had a cousin with cancer who didn’t have anyone to help her on her journey. I didn’t want that to happen to anyone else.” She feels fortunate to be able to serve others. “When I worked and was raising kids, I didn’t have much time to volunteer. Now I want to give back.” Even though she endured her own battle with cancer, she does not mention it to patients. “It’s about each patient, not about me,” she explains. McClure’s fine-tuned sympathetic ear serves her well. By listening, she often receives healing as well as giving it. That is what makes her a special friend to CTRC patients.

Beverley McClure


Keeping in Tune with Patients George Cobaugh

G

eorge Cobaugh admits he is no therapist. However, his music is soothing therapy for patients and caregivers at the Cancer Therapy & Research Center (CTRC). Cobaugh, a cancer survivor, offers piano classes at the CTRC for anyone interested in learning to play music. He teaches the basics: chords and melodies. He keeps it simple to allow students to learn to play tunes within weeks. “When I’m down, I play the piano,” Cobaugh said. “I know how music can lift up people. After all, learning to play the piano is on everyone’s bucket list.” Born and raised in San Diego, he moved to San Antonio in 2002. After a few years, he moved to Green Bay, Wisconsin. It wasn’t long until he yearned to return to the Lone Star State. He shares his love of music with his students during classes at the CTRC. “Currently, I have five students. I do a 30-minute session with each one of them. That way they get individual attention.” He recalls one patient who was anxious to learn the piano. “He had brain cancer and was undergoing radiation. Within six weeks, he was playing music. One day he walked into class and began playing ‘Amazing Grace’.” Most students stick with playing the piano even after the lessons are over. That is testimony to the enthusiasm for music and piano that Cobaugh imparts to his students. “Music brings such joy,” he said. “Most people enjoy listening to music. But knowing how to play music, well, that’s special.” His students would agree with that assessment.

VOLUNTEER OF THE YEAR • LOYCE HOLT

A

native Texan, Loyce Holt was born in Odessa and raised in San Antonio. She graduated from Incarnate Word High School before obtaining her bachelor’s degree in education from The University of Texas at Austin. Loyce taught for several years in the San Antonio and Houston areas before trying her hand in the oil business, real estate and insurance. During this time, she met the love of her life, Dan Holt. Dan and Loyce Holt married after a six-week, whirlwind courtship. While raising their family and juggling challenging careers, both Dan and Loyce went back to school to further their education. Loyce received a Master’s Degree in Library Science, and Dan obtained a Ph.D. in Higher Education Administration which eventually led him to the position of president of Blinn College. Loyce and Dan are the proud parents of two beautiful children, Brandon and Lauren; two granddaughters, Ayriel and Arianna; and a grandson, Tyson Bradford Murphy. Loyce is not a stranger to cancer. She has been told four separate times she had cancer. In 2002 she was diagnosed with Stage 3 colon cancer and in 2004 the colon cancer returned as Stage 4. In the same year, Loyce was diagnosed with a parathyroid and thyroid tumor. And in 2011 she learned she had breast cancer. Loyce battled each new bout with courage and dignity, overcoming a formidable foe. She is the consummate “cancer warrior”! A newspaper article brought Loyce to the CTRC in 2013. Her background and cancer experience drew her to CTRC. She started volunteering as a medical oncology clinic volunteer and later transitioned into the soul friend role. Loyce is a ray of light to the patients, caregivers and staff. She brings comfort and compassion to all she meets. When asked what keeps her attitude so positive, Loyce said, “I’m still here. I’m healthy. Every day is a gift from God.” Dan and Loyce Holt


The CTRC Gastrointestinal Oncology Team – led by oncologists Devalingam Mahalingam, M.D., and Sukeshi Patel, M.D. – are pictured in front of a 30-foot inflatable replica of a colon in the lobby of UT Medicine’s Medical Arts & Research Center, which is located near the CTRC on Floyd Curl Drive. The inflatable colon was there for Colon Cancer Awareness Month in March and was used to promote awareness of this disease and how early detection can save lives.

CTRC hosts first Give Cancer the Boot Run/Walk

T

he Cancer Therapy & Research Center held its inaugural Give Cancer the Boot Survivorship 5K Run/ Walk on Saturday, May 14, at the recreational running trail on the main campus of the UT Health Science Center San Antonio.

The event’s purpose was to celebrate cancer survivors and to raise awareness about cancer survivorship. The race illustrated that today’s cancer survivors continue to increase in number with better quality of life than ever before. People from all walks of life participated in the 5K – adults, kids, serious runners, casual walkers, healthcare providers, caregivers and cancer survivors. Trophies were awarded to the fastest male and female participants as well as to winners in each age group. The top finishing male and female cancer survivors received individual awards. With survivors donning red T-shirts, a sea of red shirts raced around the track, keeping up and in many cases out-pacing experienced runners and

34

n

Cancer Therapy & Research Center

n

Annual Report 2016

athletes. It was inspirational to see the strength and courage these survivors displayed, knowing that these brave people have overcome more challenging obstacles than just those faced on the race track. CTRC honored all survivors in attendance by inviting them to a special tent where they were treated to delicious treats, massages, gift bags and flowers. Survivors had the opportunity to learn about services and resources provided from organizations such as the American Cancer Society, SLEW, the Young Survivor’s Coalition, Thrivewell and a host of other non-profits serving the cancer community. The 2016 Give Cancer the Boot Survivorship 5K Run/Walk will not be the last. Next year’s event will be even better!


Honoring Loved Ones

Pilot grants create bridge to take researchers to the next level

O

ver the last seven decades, Barbara and George Williams have lost family members and friends to a variety of cancers.

“We have very sad memories of family members in our childhood years who suffered greatly from not only the disease itself, but the kinds of treatment that were offered at that time. A cancer diagnosis was a death sentence, basically, during those years,” Barbara Williams said. Williams said they understand how far medicine has progressed since that time in the diagnosis, treatment, patient care and potential prevention of cancer.

“When we asked for information about pilot projects, we were given a number to read and consider. We were amazed at the variety of projects. These projects provide the researchers with preliminary data that will be used in seeking funding for larger grant proposals. “We feel that we are making an investment in helping enhance medical advancements that have the potential for making a difference in the health of all people worldwide. No investment could be more worthwhile,” Williams explained.

Over the last three years, the Williams have selected four projects to support. These pilot projects involve an innovative treatment approach to bladder cancer “Within the last five years, George’s brother died of developed at the UT Health Science Center San a soft-tissue sarcoma that he fought for almost 10 years. Treatments offered during that time certainly Antonio, a link between pediatric and adult liver gave him extra years and good quality of life, but we tumors, a renal cell carcinoma project, and breast cancer research. know there is much to be done in combating the scourge of cancer,” she said. “After reading about pilot projects needing funding, Although the Williams supported the Cancer Therapy & Research Center through the CTRC Council’s Book and Author Luncheon and membership in the CTRC Council for many years, the couple decided to take their support to a different level after reading about the CTRC’s pilot research grant projects. Pilot grants provide a scientist the seed money needed to prove an idea has potential. This initial financial support is key to helping the researcher secure bigger grant money to fund years of laborious work.

we were inspired to choose the ones we did because they seemed to have great potential, and one in particular, ‘tugged at our heart’ because it involves hepatoblastoma, the most common type of liver cancer in children, primarily under the age of 4,” she said. In addition, the couple encourage anyone interested in cancer research to consider joining a Circle of Hope through the CTRC Council. This is a small group of supporters who join together to sponsor one pilot project. “There is no better investment of your time and resources,” Williams said.

community impact BARBARA AND GEORGE WILLIAMS FUNDED PILOT PROJECTS • Gail Tomlinson, M.D., Ph.D., division chief of Pediatric Hematology Oncology, is researching hepato blastomas in children. Dr. Tomlinson is searching for a key similarity between hepato blastomas and hepatocellular cancer in adults, which is the most common type of hepato cancer. Finding the similarities is critical to designing a clinical trial that could help both, she said. While hepatocellular cancer is a looming threat for an increasing number of adults, pediatric hepato blastomas are much rarer. Funding national clinical trials to develop drugs to treat them alone is difficult, Dr. Tomlinson said. She has identified a possible key element that appears in both cancers, and the next step involves intensive analysis to develop a drug to target it. • Karen Block, Ph.D., former associate professor of nephrology at the UT Health Science Center San Antonio, and Denis Feliers, Ph.D., assistant professor of cell biology at the Health Science Center, are working on kidney cancer research. The gift to Dr. Block and Dr. Feliers will be used to develop a therapy for kidney cancer, among the most malignant cancers in the U.S. with a high incidence in South Texas. The researchers are examining what drives the process at the cellular level. When the wrong protein is present in kidneys, it gives rise to kidney cancer, and oxidative stress is what allows the wrong protein to be present.


Circles of Hope Come to CTRC A CTRC Council Circle of Hope is a group of 10 couples/individuals who raise $25,000 by each contributing $2,500. By raising this amount, they are able to support a pilot research study and directly support brilliant research that may one day lead to a cancer cure. The idea of combining resources to fund groundbreaking research is directly borrowed from Impact SA, a local organization that raises and donates hundreds of thousands of dollars each year to local nonprofits. CTRC Council President Liz Conklyn and two board members, Cynthia Schluter and Lora Watts, introduced this concept to the council during a planning session in 2014. The idea was endorsed by the board and is now one of the projects they oversee each year. Members of the CTRC Council Circles of Hope meet in a social setting and Ian M. Thompson, Jr., M.D., CTRC director, introduces the abstracts of several pilot studies. Members vote on the study they would like to fund and are invited to the CTRC about six months later for a presentation by the investigator they are funding. At year’s end, the circle members receive a written report of what was accomplished through the study. Two CTRC Council Circles of Hope have been formed, and the third one is seeking a few more members to be complete. For more information or to join this effort, call 210-450-5571 or email CTRCCouncil@uthscsa.edu.

36

n

Cancer Therapy & Research Center

n

Annual Report 2016

Circle of Hope supports pilot colon research study

C

olorectal cancer is the second most common cause of cancer death in the United States. While many patients are cured through surgery and chemotherapy, patients have a considerable risk for recurrence within the colon or at other sites in the body. These patients can take aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) to decrease the risk of the cancer returning, but these are wrought with side effects from Dr. Sukeshi Patel long-term use that include bleeding, stomach irritation and kidney problems. Sukeshi Patel, M.D., assistant professor of medical oncology at the Cancer Therapy & Research Center (CTRC), working with Michael Wargovich, Ph.D., and James L. “Jay” Morris Jr., Ph.D., from the Department of Molecular Medicine, found a compound called epigallcatechin gallate or EGCG, commonly found in tea, that might be able to prevent recurrence of colorectal cancer with little or no longterm side effects.

EGCG works by reversing the silencing of some genes in colorectal cancer. In the early stages of colorectal cancer, some genes important for controlling cell growth and proliferation are turned off by what scientists call epigenetic mechanisms. Epigenetic events in the cell normally help to turn genes on and off in the process of development. In cancer cells, these events often turn off genes that would otherwise help prevent the growth of the cancer. Work in the laboratories of Drs. Wargovich and Morris has shown that this is the case in colorectal cancer and that EGCG is effective in preclinical studies of colorectal cancer. Dr. Patel stepped in to design a clinical pilot study to evaluate the chemopreventive effects of EGCG in patients who have already had surgery to remove their colorectal cancer. This natural agent has shown few if any side effects to date and is very promising. This pilot study was selected for funding by one of the CTRC Council Circles of Hope in 2016.


25th Anniversary

Book and Author Luncheon Celebrates Milestone

T

he annual San Antonio Express-News Book & Author Luncheon is an eagerly anticipated event for many in San Antonio and surrounding areas. This popular luncheon was first held in 1991 and was the brainchild of Karen Norman Mueller, who attended a book and author event in Tucson, Arizona, with her sister. Wanting to bring an event like this to San Antonio, Mueller had a hard time finding someone to take it on until a fateful day when Larry Walker walked into a St. Luke’s Lutheran Hospital Foundation board meeting and was introduced as the new publisher of the San Antonio Express-News. “I knew immediately this was the person to make this dream a reality,” said Mueller, who approached Walker with her idea, and he immediately saw it as just the kind of event the local newspaper should support. Walker then introduced Mueller to his wife, Caroline, and the rest, as they say, is history. Mueller began researching how other cities’ book and author events were organized and produced. She and Caroline Walker attended several in Texas. Most events supported local libraries and involved several hundred guests, but the event in Phoenix raised money for the National Kidney Foundation. Done on a large scale and promoted throughout the city, the group in Phoenix raised a lot of money. This sparked the idea to have San Antonio’s event benefit the Phase I Drug Program at St. Luke’s Lutheran Hospital, a program for which the hospital was constantly seeking funding. After St. Luke’s was sold, the Phase I program was moved to the Cancer Therapy & Research Center (CTRC) and so did the proceeds of the event. Raising money for cutting edge treatments and therapeutics has always been the focus of the San Antonio Express-News Book & Author Luncheon. Judyth Rigler, San Antonio Express-News book editor, led the effort to find the authors. She did an amazing job of seeking out potential guest authors at

events around the country so she could hear them speak. She knew that long-term success would depend not only on the authors’ literary ability, but also on their ability to relate to those in attendance. Mueller is proud that this event has remained strong. She believes this is due to the hard work of many and also because of its strong mission to support cancer research. Because cancer touches everyone, Mueller said people are eager to support research designed to find better ways to diagnose and treat the awful disease. On November 11, a group of 1,200 attendees celebrated the silver anniversary of the Book and Author Luncheon with featured authors Imbolo Mbue, Paulette Jiles, Candice Millard, Andrea Beaty, Lucinda Scala Quinn and John T. Montford. As always, these best-selling national authors complimented the UT Health Science Center San Antonio and the CTRC Council for holding one of the best book and author events in the U.S. Year after year, authors (more than 125 to date) have been impressed with San Antonio’s unique brand of hospitality and devoted crowd. A highlight of the event each year is Coleen Grissom, Ph.D., who serves as the “Ms. of ceremonies.” Dr. Grissom, an English professor at Trinity University, has been at the helm all these years. The audience enjoys her witty observations about the all-too-common pitfalls of the English language and the way she lovingly pokes fun at anyone – all while sharing her infectious love of literature. With the continued efforts of devoted leaders and volunteers, the Book and Author Luncheon should enjoy another 25 years. Coleen Grissom, Ph.D., the “Ms. of ceremonies”

Cancer Therapy & Research Center

n

Annual Report 2016 n

37


Many thanks to our community for supporting the CTRC

CTRC COUNCIL DELIVERS FREE PATIENT TRANSPORTATION For patients receiving treatment for cancer, transportation can be a huge hurdle to overcome. This is especially true for those who are unable to drive. Through funding from the CTRC Council, the Cancer Therapy & Research Center (CTRC) offers free patient transportation.

CITY OF SCHERTZ Proceeds from the Wilenchik Walk for Life, held each fall in honor of Tony Wilenchik, benefit the CTRC’s Institute for Drug Development. Wilenchik was a former city councilman and civic leader who lost his battle with cancer in 2009. Since then, the annual walk has raised more than $160,000.

The service extends to all patients who live inside Loop 1604, the outer highway loop encircling San Antonio. A caregiver, relative or friend can accompany each patient. The transportation service is managed by the CTRC’s Patient and Family Services group, which operates three vehicles driven by professional drivers. The vans can accommodate eight to 12 passengers. Patients are picked up at their residences up to two hours before their scheduled appointment at the CTRC. Once their treatments are finished, their return trip home is arranged. To qualify, patients must be over 60 years of age and meet certain financial guidelines. Patients also must be mobile because the vehicles are not equipped with wheelchair lifts.

Wilenchik Walk for Life

SAKS FIFTH AVENUE In honor of Breast Cancer Awareness Month in October, Saks Fifth Avenue San Antonio donates 100 percent of the sales from their Key to the Cure designer T-shirts and 2 percent of all sales during a four-day Friends and Family Shopping Days to the CTRC. They also host a special event to recognize outstanding cancer researchers, doctors and nurses. Saks has raised more than $116,000 since 2009.

38

n

Cancer Therapy & Research Center

n

VULCAN MATERIALS Longtime CTRC supporter Vulcan Materials sponsors two great events to support the work of the CTRC. In September 2015, the Vulcan team held its first golf tournament at TPC San Antonio. Two hundred golfers participated in this inaugural event. In April 2016, Vulcan Materials held the 22nd Annual Funshoot and raised approximately $140,000 for the CTRC. A team of more than 15 Vulcan employees organize the event which includes 15 sponsors, 69 teams of four shooters, 24 silent and 12 live auction items. Vulcan and its devoted team of volunteers have raised

Annual Report 2016

approximately $2.3 million for the CTRC through their hard work in producing these successful and fun events. CTRC Council The more than 400 members of the CTRC Council work tirelessly each year to volunteer their time and host multiple events benefitting the CTRC. This year, the CTRC Council donated $267,000 from funds raised through their membership drive, Partner Shopping Card sales and Spring Luncheon. Funds donated support research, patient assistance, and education.


A Lasting Legacy ANONYMOUS GIFT ADVANCES PROMISING RESEARCH Cordillera Ranch CTRC Research Circle Magical Evening Results in $200,000 for Research Jan and Frank Newton and Diane and Phil Pfeiffer hosted a special evening at Cordillera Ranch in Boerne on May 12. The hosts invited fellow residents of the Cordillera community to have dinner with cancer experts from the Cancer Therapy & Research Center (CTRC) and learn more about the latest breakthrough discoveries and cutting-edge cancer treatments. Keynote speaker, Ian M. Thompson, Jr., M.D., director of the CTRC, provided an overview of the CTRC and examples of the innovative cancer research being conducted there. Everyone was inspired by Dr. Thompson and the other CTRC specialists who joined the guests at their tables to engage in personal conversations about the latest cancer research and answer questions. Dr. Thompson discussed the CTRC’s bold vision to obtain two Specialized Programs of Research Excellence (SPORE) grants from the National Cancer Institute (NCI) within the next two years in prostate cancer and breast cancer. If successful, the grant awards would provide significant federal funding from the NCI – up to $12.5 million over five years for each SPORE. In order to successfully obtain this federal funding, a group of 20 to 30 researchers must first conduct major pilot research studies to prove their concepts have validity. Each SPORE consists

of four or five pilot research projects that will each cost $100,000 in seed money to advance their breakthrough research. Even if the SPOREs are not funded by the NCI, the research efforts from each SPORE initiative will likely result in four to six grants totaling $5 million to $7 million to support investigators at the CTRC. As a result, the frontiers of knowledge will be expanded and will contribute to turning innovative cancer discoveries into new treatments to save more lives. Dr. Thompson presented a unique opportunity to the dinner guests to join a Research Circle at the CTRC. Phil Pfeiffer announced he and Diane had decided to join the circle as did Jan and Frank Newton. Before the night was over, 10 couples had decided to pool their resources ($10,000 from each couple paid over two years) to provide $100,000 in vital seed funding to advance this important cancer research initiative. Dr. Thompson and the other CTRC physicians and scientists were overwhelmed by the amazing level of support and generosity! Dr. Thompson announced the CTRC will be matching each donation dollar for dollar for the SPORE initiative. Therefore, the $100,000 commitment received from the Cordillera Ranch Research Circle will actually provide $200,000 in support. What a magical evening!

The Cancer Therapy & Research Center (CTRC) is grateful for a recent gift of more that $500,000 from a former patient to support life-saving cancer research. In recognition of the compassionate care received at the CTRC, the patient’s motivation was to leave a legacy that would help future cancer patients. “This remarkable gift truly has the potential to change lives. We are investing this patient’s thoughtful gift to assist physicians and scientists in advancing their research that will lead to better ways to diagnose, treat, and even prevent cancer. As the director of the CTRC, I am always touched to think of a patient who would leave their life’s treasure to make the path a little better for those of us who follow. It is an inspiration to see that kind of generosity” said Ian M. Thompson, Jr., M.D., CTRC director. CTRC supporters Kelley and Pat Frost have made a bequest to the CTRC in their estate plan because they believe in the lifesaving work happening each day. “We support the advances in cancer research and treatment being made by the Cancer Therapy & Research Center and are honored to be able to continue this legacy through the planned giving program. Life is the most worthy investment of all, and this gift contributes to the lives of others,” they said.


CTRC Board of Governors THANK YOU FROM THE CTRC BOARD OF GOVERNORS On behalf of the entire CTRC Board of Governors, I thank you for your generous and steadfast support of our cancer center. Our Board of Governors, comprised of 150 community leaders, supports the life-saving work of the CTRC in three key areas: acting as ambassadors for the CTRC in the communities in which we live and work; providing strategic support and feedback on CTRC operations, recruitments and initiatives; and investing in the innovative cancer research of the CTRC through philanthropic support, both personally and by inviting others to join in the cause.

(L-R) Board member Mark E. Watson, Jr. and his wife, Courtney

From research beginning in the lab to Phase I clinical trials, our CTRC is committed to excellence at every stage of the quest to eliminate cancer. Through recruitment of world-renowned researchers and clinicians, investment in cutting-edge therapies and treatments, training the next generation of cancer doctors, and delivery of patient-focused care, the CTRC provides patients and their families the most advanced and compassionate care. Recognized by the National Cancer Institute as a Designated Cancer Center, our CTRC continues to build on its 42-year history of commitment to the eradication of cancer. Our CTRC continues to grow and develop its potential to devote resources to innovative drug development, serve greater and farther-reaching patient populations, and expand our expertise in broader and more sophisticated treatments to support patients and their families in the fight against cancer.

(L-R) Board members Mark Wright, Lori Wright, Taddy McAllister and Edith McAllister

Your partnership with CTRC is vital to its ongoing success, and we thank you for your support of our Cancer Therapy & Research Center – the answer to cancer. Karen Lee Zachry Chair, CTRC Board of Governors

Board member Carl Raba with his daughter Cathy and Board member Charlie Cheever with his wife, Nancy

40

n

Cancer Therapy & Research Center

n

Annual Report 2016


Karen Lee Zachry, Chair Lori Wright, Chair-Elect Christine D. Alderete Wayne Alexander Ernesto Ancira Yolanda Anderson Dr. Forrest Aven Emerson Banack, Jr. Rose Marie Banack Louise D. Beldon Michael D. Beldon Michael Belz Beverly A. Birnbaum Michael L. Birnbaum Stanley L. Blend Donna Block Mary Ballenger Brook Steven R. Brook Jamie Browning J. Bruce Bugg, Jr. Pam Burdick T. Randall Cain Jim Callaway Dya C. Campos Alonzo Cantu Charles E. Cantu ChaCha Cavazos Charles E. Cheever Jean Cheever Graciela Cigarroa Lisa H. Cohick Liz Conklyn Louis R. Cooper Bob Cowan Lynn Finesilver Crystal Dr. Suzanne Marlar Dabbous J. Russell Davis Laura Dixon Tom Dobson

Barbara B. Dreeben Gerald Z. Dubinski Stephen M. Dufilho Arthur Emerson Helen Eversberg Brian Feld Renee Flores Dr. Kelley Frost Patrick B. Frost Steven W. Garza Leo Gomez James W. Gorman James Greenwood Rhonda Gurinsky Robert E. Gurwitz Kenneth J. Halliday Patricia Hayes Roxana C. Hayne Christine L. Haynes Joe N. Haynes Karen L. Heintz Roger R. Hemminghaus F. Peter Herff Karen H. Herrmann Cari S. Hill Janet Holliday Kaye D. Holt Linda Hummel Robert L. Jemerson Kathryn Mays Johnson Laurie A. Kaplan John L. Kauth Edward B. Kelley Nancy L. Kelley Margie Klesse Edward K. Kopplow

John C. Korbell Carolyn Labatt Milton B. Lee Andreae LeMaistre Dr. Charles A. LeMaistre Molly Light Nancy Loeffler Jeff Lott Katie Luber Mike Manuppelli Janey Briscoe Marmion Tracie Martin Edith S. McAllister Taddy McAllister Walter W. McAllister David P. McGee Joe C. McKinney Sherry McNeil Dr. Thomas M. McNish Yona McNish Mark Meador Balous T. Miller Lou Miller Jennifer Moriarty Karen Norman Mueller Lee Mueller Tim Musgrave Terrie E. Musselman Dr. Dacia H. Napier Jan Newton Phil Norman Michael J. Novak Margie K. O’Krent Sam O’Krent Judy Palans Camilla M. Parker Donna M. Pasacrita

Phil Pfeiffer Jane Cheever Powell Duane C. Pozza Dr. Carl F. Raba, Jr. Thomas R. Ransdell Jack C. Richmond Andrea F. Rodriguez Robert A. Rosenthal Shawn Rosenzweig Louis E. Rowe Dianna Roy Jane R. Satel Dona Schenker Richard T. Schlosberg Lisa M. Sechler Stephen D. Seidel C. Frederick Shannon DeeAnn Simpson Dr. G. P. Singh James B. Smith Dennis W. Stahl Harris J. Sterling Ruth Eilene Sullivan Nancy Torgerson Vernon Torgerson Mary West Traylor Jon Turner W. Lawrence Walker AnaPaula Watson Mark E. Watson, Jr. Lora Watts Charles Martin Wender Kenneth L. Wilson Mertie Wood Gary V. Woods Mark H. Wright Lois F. Yancy

(L-R) Board members Russell Davis, Louise and Mike Beldon and Phil Norman

Board member Bob Cowan and his wife, Diane, and board member Bob Gurwitz and his wife, Gail

(L-R) Board members Andi and Mickey LeMaistre with Ian and Donna Thompson

Cancer Therapy & Research Center

n

Annual Report 2016 n

41


Community Leadership & Support CTRC COUNCIL

CTRC FOUNDATION The CTRC Foundation was founded in 1991 as the CTRC Endowment Corporation with initial funding of $50,000 provided by Dr. Burton Grossman. Since that time, the endowment has increased substantially, with the largest funding to date totaling $85 million from the sale of Ilex Oncology shares in 2005.

The CTRC Council has supported the life-saving work of the Cancer Therapy & Research Center for 32 years. Thanks to our members and very hard working Board of Trustees, these volunteers have raised more than $4.5 million toward patient assistance and funding research over those years.

The CTRC Endowment Corporation became the CTRC Foundation following the merger of the Cancer Therapy & Research Center with the UT Health Science Center San Antonio in 2007.

The first half of each year is dedicated to the Patient Assistance Fund. Monies from the Spring Luncheon and the Big Give are donated to help those patients who struggle with the economic consequences of their cancer diagnosis.

Over the past nine years, the CTRC Foundation has contributed approximately $48 million to the support of CTRC. The foundation’s current endowment balance is $33 million. Grants have been made for faculty recruitment, research programs, equipment purchases, patient support, National Cancer Institute (NCI) support, and general CTRC operations.

Patient assistance includes the food pantry, nutritional supplements, Soul Friends, Patient Ambassadors and much more. Particularly important is transportation assistance through both owned vans and subsidized rides. You can’t be treated if you can’t get to treatment.

The CTRC Foundation consists of 10 board members: Judy Palans Louise Beldon Tom Ransdell Jim Callaway W. Lawrence Walker Jr. Barbara Dreeben Mark E. Watson Jr. James W. Gorman Jr. Gary V. Woods John Kauth The board meets as necessary to review investments and consider funding requests from the CTRC for the continuation of endeavors aimed at fulfilling the primary mission of the institution – to serve the people of Central and South Texas by advancing cancer research, treatment, prevention and education.

The second half of the year is focused on research support. This year, funds raised through the Partners Shopping Card program and dedicated events, such as Rudy’s Cup for the Cure, will make the final payment on the $1 million pledge for the CTRC Council Distinguished Chair in Oncology. This commitment helped fund the amazing work of Michael J. Wargovich, Ph.D., who focuses on anti-inflammatory ingredients in traditional foods and medicines that have disease-fighting properties resulting in reduced risk of cancer occurrence or recurrence. Other research funds come from our partnership with the San Antonio Express-News for the Book & Author Luncheon and pledges from our Circles of Hope. The council has been particularly pleased to support a number of pilot studies, launching important new work by the brilliant researchers of the CTRC.

As chairman of the CTRC Foundation Board, I proudly share in the continued commitment of our members to serve as stewards of the endowment fund for the future of our community.

The excellence and compassion of the physicians, nurses, scientists and staff of the CTRC continue to inspire our work. The courage of the patients and their families continues to motivate all we do.

Gary Woods Chair, CTRC Foundation Board

Liz Conklyn President, CTRC Council

42

n

Cancer Therapy & Research Center

n

Annual Report 2016


CTRC Council builds on successful tradition The CTRC Council is a non-profit organization founded in 1984. With more than 400 members, the devoted group is dedicated to volunteering its time and efforts to benefit the Cancer Therapy & Research Center (CTRC). The CTRC Council’s volunteer efforts involve helping patients undergoing treatment at the CTRC and serving as the main volunteer force behind the successful San Antonio Express-News Book & Author Luncheon. This event, held each fall, has raised more than $3.5 million for the Phase I clinical trial program at the CTRC. During its 32-year history, the council has contributed approximately $4.5 million to the CTRC. The main fundraising efforts are the Partner Shopping Card and the Spring Luncheon. Each fall, the Partner Shopping Card is sold for $50 and entitles the owner to a 20 percent discount during designated shopping days at more than 300 San Antonio area retailers. This fundraising effort has raised approximately $2 million over the past 16 years in support of cancer research. The Spring Luncheon is an opportunity for council members and guests to be entertained and encouraged all while supporting the needs of cancer patients. Olympic gold medal winner Josh Davis was the featured speaker at this year’s event. Davis’ motivational talk, which included personal comments about the CTRC where his mother was treated throughout her battle with cancer, left the audience inspired.

Cancer Therapy & Research Center

n

Annual Report 2016 n

43


CTRC MAJOR GIFT HIGHLIGHTS $1 MILLION TRIBUTE FROM JODI AND RICHARD WELLS FOR THE FOURTH CONSECUTIVE YEAR For the fourth consecutive year, Jodi and Richard Wells and their family have donated an unrestricted $1 million gift to the Cancer Therapy & Research Center (CTRC) to support the cancer center’s programs, innovative cancer research, compassionate patient care and assistance to cancer patients in need. Richard Wells, who lost his beloved father, Robert Milford Wells, to lung cancer in 2010, feels blessed to be able to make these significant contributions to support the efforts of Ian M. Thompson, Jr., M.D., CTRC director, and his team of exceptionally talented physicians, scientists, nurses and staff. “We are incredibly honored and proud to help Dr. Ian Thompson and his team with these gifts made in memory of my father in the hope of helping to eradicate cancer in our lifetime,” Wells said. Dr. Thompson emphasized the magnitude and impact of the Wells family gifts, “This remarkable

level of support and generosity is equivalent to having a $20 million endowment (which distributes 5 percent per year) that helps me as director of the cancer center to make vital investments in our important programs, breakthroughs in cancer research and drug development, and support for our talented teams who provide the most advanced cancer care for our patients. “We are deeply grateful to Jodi and Richard and their family for their confidence in the mission of the CTRC and for the profound impact made possible by their invaluable support,” said Dr. Thompson. $750,000 IN CTRC CABINET GIFTS SUPPORT THE IDD At the first CTRC Board of Governors meeting this year, CTRC Cabinet Co-Chairs Karen Heintz and Lori Wright were elated when they announced the CTRC Cabinet gifts received in calendar year 2015 had reached their goal of $750,000. This is the highest level of cabinet support in any given year since the annual giving fund was established in 1996. How fitting to mark the 20th anniversary of the CTRC Cabinet with a record-breaking year! Carl Raba has joined Heintz and Wright this year as the CTRC Cabinet’s third co-chair. This dynamic trio is well on its way of achieving the $750,000 goal again this year in support of the life-saving work of the CTRC’s Institute for Drug Development (IDD). Each of the three co-chairs knows firsthand how cancer impacts lives. They have all seen loved ones and close friends diagnosed or taken by the disease.

(L-R) Richard Wells, Jodi Wells and Dr. Ian Thompson at the dedication ceremony to name the “Robert Milford Wells Center for Innovation in Cancer Therapies” in memory of Richard’s father who lost his battle with lung cancer.

44

n

Cancer Therapy & Research Center

n

Heintz, whose husband Phil battled nonHodgkin’s lymphoma for several years until he passed away in 2009, said, “Treatments at the CTRC extended Phil’s life and the quality of his

Annual Report 2016

life until his passing. Not only did he receive the most advanced treatment, he was treated with great patience and kindness by the doctors, nurses and staff, and that made a positive difference in his life and mine. The treatments discovered at the IDD are amazing and are truly helping patients.” Wright, whose husband Mark was diagnosed with brain cancer several years ago, agrees. “The CTRC is a gem in our hometown. We want to be proactive and tell the world so the CTRC can continue to purchase needed equipment and recruit the best and most talented researchers. When you see patients thriving as a result of successful cancer treatment efforts, it’s exciting and brings so much hope for the future,” she said. With exceptional treatment and care, Mark is doing very well. They both continue to devote their time to supporting the CTRC. Raba, whose daughter Cathy was diagnosed with a rare type of cancer in 2011, echoed Heintz and Wright’s praise of the CTRC. “Cathy’s doctors at the CTRC and UT Medicine San Antonio are the best. We have been overwhelmed by their exceptional skills as surgeons as well as by their sensitivity and compassion. San Antonio needs more doctors like them. Patients like Cathy don’t have to travel outside of the city for this kind of care. It’s right here.”


$1 MILLION GIFT OF HOPE FROM LINDA AND ED WHITACRE A $1 million gift from Linda and Ed Whitacre will support the pilot cancer therapeutic clinical trials program at the CTRC as well as fund an education and awareness campaign to Linda and Ed Whitacre highlight the clinical trials and expertise available to patients battling cancer.

two National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) grants – one in prostate cancer and one in breast cancer. These types of grants are among the most prestigious grants awarded by the NCI – each grant providing up to $12.5 million over five years. “We are honored and grateful to this generous couple for their significant investment in our efforts to seek two SPORE grants from the NCI. In order to be successful in our quest, our teams of 20 to 30 researchers must first conduct critical pilot research studies to prove their concepts. This gift is the first step in advancing these breakthrough discoveries,” said Dr. Thompson. $325,000 CONTRIBUTION FROM VALERIE AND JACK GUENTHER FOR “WINGS OF HOPE”

Increasing the number of clinical trials for cancer patients and raising awareness among patients and physicians of new innovative treatments are among the key goals for the CTRC.

Longtime supporters Valerie and Jack Guenther made another major gift to the CTRC to commission an inspirational outdoor art sculpture that will be dedicated to cancer patients.

Ian M. Thompson, Jr., M.D., director of the CTRC, said, “We are deeply grateful to Linda and Ed for their generosity in helping us provide the most advanced new therapies for our patients and ensuring that every single patient in San Antonio and South Texas is aware of these unique opportunities. This gift will accelerate the development of new cancer cures through the work of our extensive teams of scientists and physicians.”

“Wings of Hope,” designed and created by world-renowned artist Kent Ullberg, will be made from bronze patina for the hands and polished stainless steel for the wings. Symbolizing hope for all cancer patients, the 20-foot sculpture is expected to be completed by early 2017.

$505,000 RECEIVED FOR PROMISING SPORE INITIATIVE Intrigued by the SPOREs initiative that Dr. Thompson outlined during a recent lunch meeting, an anonymous donor contributed $505,000 to support the CTRC’s efforts to seek

CTRC Director Ian M. Thompson, Jr., M.D., stated, “We were overwhelmed by Valerie and Jack’s generosity to commission this important work of art for the CTRC. We look forward to its completion and to celebrate the unveiling of this masterpiece that will inspire our patients and their families as well as our physicians, scientists, nurses and staff for generations to come.”

$100,000 LEGACY GIFT FROM LANG GLOTFELTY ESTATE Lang Glotfelty was “bigger than life” and all who were blessed to have known him were touched and inspired by his energy, passion and great sense of humor. Glotfelty, who was a successful entrepreneur for more than 40 years, remained very active in his community after selling his businesses. He didn’t know the meaning of slowing down in retirement. He was a member of many non-profit boards, including the CTRC Board of Governors, Score, Master Leadership Program and The Blood and Tissue Center. Lang and Judy Glotfelty “When Lang and his wife, Judy, told me that they wanted to make a difference in the fight against cancer, I knew it was very personal for them. Lang decided to name the CTRC in his estate plans, and he wanted his legacy gift to be used where the need was greatest,” said Dr. Thompson, who was Lang’s physician, surgeon and oncologist. Judy Glotfelty, a 10-year survivor of pancreatic cancer and CTRC patient, said, “Lang loved Dr. Thompson and the CTRC. We knew first-hand the important work being done here and are honored to make this gift in Lang’s memory.”

Cancer Therapy & Research Center

n

Annual Report 2016 n

45


LEADERSHIP COMMUNITY SUPPORT CASH DONATIONS, PLEDGES AND BEQUESTS TO CTRC AS OF AUGUST 31, 2016 MAJOR GIFTS CTRC Foundation Jodi and Richard Wells Linda and Ed Whitacre Edna and Dale Walsh Valerie and Jack Guenther Dickson-Allen Foundation Estate of Lang Glotfelty

CTRC CABINET Impact Circle ($100,000 +) Jodi and Richard Wells

Patron’s Circle ($20,000 +) Charles C. Butt Dacia and Lanham Napier Lori and Mark Wright

Leadership Circle ($10,000 +) Robert A. and Kathey K. Anderson Foundation Checks In The Mail, Inc. Patty and Bob Hayes Karen L. Heintz Rose Marie and John L. Hendry, III Margie and Bill Klesse Kathy and Tim Musgrave Marian Oppenheimer Dee and Jack Willome Gary V. Woods

Director’s Circle ($5,000 +) Ceila and Richard Acosta Lexie and Rowan Altgelt Pam and Art Burdick Nancy and Charlie Cheever Mr. and Mrs. Charles Ebrom Kris and Jim Ellis The Alfred S. Gage Foundation

46

n

Cancer Therapy & Research Center

Kolitz Foundation, Inc. Amy Shelton McNutt Charitable Trust Kathi and John Oppenheimer Camilla and Bill Parker Cheryl and John Schoolfield Mr. and Mrs. Richard C. Traylor Karen Lee and David Zachry

Sustainer’s Circle ($2,500 +)

Argyle Foundation / Jan and Bob Marbut Dianne and Richard Azar Mr. and Mrs. William D. Balthrope Beverly and Mike Birnbaum Dr. Kelley L. Frost and Mr. Patrick B. Frost Lindsay and Jack Guenther, Jr. Valerie and Jack Guenther Tina and Joe Haynes A. Jackson Holt Abigail and George Kampmann Molly Light McClure Charitable Foundation Judy and Palmer Moe Margie and Sam O’Krent Carl F. Raba, Jr. Ann and Tom Ransdell Pat and Marcy Stehling Mr. and Mrs. Vernon D. Torgerson, Jr. Sandra and Dale Tremblay Suzanne and Dick Wade Courtney and Mark E. Watson, Jr.

Partner’s Circle ($1,500 +)

Mr. and Mrs. Ben Adams Mr. and Mrs. James Adams Mr. and Mrs. Joseph V. Alderete, Jr. Mindi Alterman and Dr. Glenn Halff J.R. Avant Dr. and Mrs. Forrest Aven Mr. and Mrs. Emerson Banack, Jr. Louise and Mike Beldon Nel Belt Ann D. Biggs Linda and Stanley Blend Donna Block

n

Annual Report 2016

Margery L. Block Mary and Steve Brook Mike and Louise Burke Ron and Genie Calgaard Paula and Jim Callaway Mr. and Mrs. Richard W. Calvert Charles E. Cantu Mr. and Mrs. Michael Belz Mrs. James M. Cavender, III Chris Cheever Jean M. Cheever Mr. and Mrs. Henry Cisneros Lisa and Don Cohick Mr. and Mrs. Robert L. Cook, Jr. Diane and Bob Cowan Dr. Gary Forrest Cox Lynn Finesilver Crystal Mr. and Mrs. Charles H. Davis Terry and Russell Davis Mr. Luis A. De La Garza and Ms. Sherry Lynn Hatcher Justice Preston H. Dial, Jr. Barbara and Alan Dreeben Mr. and Mrs. Gerald Z. Dubinski, Sr. Steve and Adele Dufilho Jimmie Ruth and Dick Evans Mr. and Mrs. Carl Fellbaum Renee Flores Israel Fogiel Mr. and Mrs. Eduardo Garza Mr. and Mrs. S. J. Goebel Dr. and Mrs. Roy R. Gonzales, Sr. Gail and Bob Gurwitz Alvin Hayes Roxie and Jim Hayne Dot and Roger Hemminghaus Lynn and Peter Hennessey Shirley J. Herres (deceased) Karen and Ronald Herrmann Mr. and Mrs. Bruce Hardy Chilton Hill James Hockstadt Anne Holt and C.D. Schultz Mr. and Mrs. Leonard Holzman Billie-Kite Martin Howlett Kathy and Bill Johnson Janet Annabelle Jones Mr. Mitchell H. Kaliff and Mr. Bruce A. Smiley-Kaliff Laurie and Michael J. Kaplan Joan and Pat Kennedy

Lisa and Ed Kopplow Barbara C. Kyse Carolyn and Joe Labatt Judy Lachman Bill N. Lacy Sarah and Milton Lee Fred C. Lepick, Jr. (deceased) Mike A. Manuppelli Patty McCarroll Sherry and Laird McNeil Yona and Tom McNish Julie and Balous Miller John C. Mitchell Dr. and Mrs. Claude L. Nabers Jan and Frank Newton Sue Oppenheimer Pat and Keith M. Orme Sheri and Manny Ortiz Diane and Phil Pfeiffer Susan and Allen Pierce Mr. and Mrs. George Plummer Jane Cheever Powell and Tom Powell Karen Presley Dr. Amelie and Mr. David Ramirez Katie and Jim Reed Laura and Jack Richmond Arthur and Helene Riklin Mr. and Mrs. Stanley D. Rosenberg Jane and Jimmy Satel Mr. and Mrs. William Scanlan, Jr. Mr. and Mrs. Louis Scantland Mr. and Mrs. Richard T. Schlosberg, III Lisa and Kelly Sechler Jon H. Smith Lynn and Sam Stahl Mr. and Mrs. Thomas A. Stephenson Francie and Harris Sterling Patricia G. Steves Nana and Julian Stewart Joci and Joe Straus Ruth Eilene Sullivan The Doctors Donna and Ian Thompson Cathy Raba Turcotte Martha and Geoffrey Weiss Linda and Ed Whitacre Barbara and George Williams Wong Family Enterprises Ltd. Mertie and Dale Wood Mr. and Mrs. Carl E. Wulfe Dr. and Mrs. James William Yancy


2016 BREAST CANCER SYMPOSIUM Premier ($200,000 +) Lilly Oncology Genentech  

Angel ($125,000 +) AstraZeneca Genomic Health Pfizer Oncology

RareCyte, Inc Syndax Pharmaceuticals, Inc Xoft, a subsidiary of iCAD, Inc

Special Thanks Susan G. Komen Foundation

SAN ANTONIO EXPRESS-NEWS BOOK & AUTHOR UNDERWRITERS Nobel Laureate ($20,000 +)

bioTheranostics Novartis Oncology 

Mays Family Foundation San Antonio Express-News Valero Energy Foundation

Major Supporter ($50,000 +)

Pulitzer ($10,000 +)

Patron ($80,000 +)

AbbVie Inc. Celgene Corporation Eisai Inc Medivation, Inc  Myriad Genetic Laboratories, Inc. NanoString Technologies TESARO

Contributers ($25,000 +)

Agendia, Inc  Counsyl Dignitana, Inc / DigniCap Heron Therapeutics, Inc Research to Practice R-Pharm US  Spectrum Pharmaceuticals, Inc.

Donors ($10,000 +)

Amgen Celldex Therapeutics Color Genomics Faxitron Helsinn Therapeutics US, Inc   Integrated Oncology IntraOp Medical Corporation  Invitae Lumicell MacroGenics, Inc Med Fusion Medtronic Menarini Silicon Biosystems Merck & Co., Inc. Miraca Life Sciences Paxman Coolers, Ltd Prelude Corporation Quest Diagnostics

AT&T Klesse Foundation Silver Eagle Distributors

Best Sellers ($5,000 +) Ancira Enterprises Argo Group US Frost Bank Karen and Tim Hixon Nancy and Ed Kelley The Tobin Endowment

Program Design Sponsor ($5,000 +) Causality Studios

First Editions ($2,500 +)

Argyle Foundation Bank of San Antonio Burdick Custom Homes Helen Groves C. H. Guenther and Sons, Inc. Julian Gold, Inc. Dianna and Drew Roy San Antonio Spurs, LLC Zachry Corporation

Classics ($1,500+)

Barb and Wayne Alexander Paula and Jim Callaway Catholic Life Insurance Nancy and Charlie Cheever CITI H-E-B Bonnie and John Korbell Karen and Lee Mueller Norton Rose Fulbright US, LLP Pizza Hut of San Antonio University of the Incarnate Word J. Tullos Wells

Special Thanks Carvajal Pharmacies Janet Holliday and the CE Group Dr. Coleen Grissom The Prestigious Mark Scobey Moving and Storage The Twig Book Shop

SAN ANTONIO EXPRESS-NEWS BOOK & AUTHOR PROGRAM ADVERTISERS Akin, Doherty, Klein and Feuge Allstate Benefits Ameritas Life Insurance Corp. Andie and Barbara, Inc. Arthur P. Veltman and Associates, Inc. Beckwith Electronic Engineering Britton Orthodontics, PA Budget Movers Builder Factory Store Builders Interior Products Burdick Custom Homes, Inc. Bygones Caprock Cheever Books Law Offices of Robert Cowan, Jr. Judy Dalrymple DOCUmation Dominion Design and Integration Dr. Rogers Wellness and Weightloss Center, P.A. Ecumenical Center Eva’s Heroes Ferguson Bath, Kitchen, and Lights Gallery Guardian Life Insurance Company Gurinsky’s Fine Jewelry Brehrn Havel, CPA Inside Outside Wellness Center John-William Interiors Kalig Auto Group Roberta Krueger, MD Lee Dental Lighting Inc. Maldonado Nursery and Landscaping, Inc. McNay Art Museum MetLife Mutual of Omaha Insurance Company North Park Lexus of San Antonio O’Krent’s Abbey Flooring Pristine Pools RK Group/Catering by Rosemary

Reznikov’s Fine Jewelry San Antonio Chamber Orchestra San Antonio Lighthouse for the Blind San Antonio Portfolio Real Estate Cindy and David Schneider Schulz Landscaping and Design Security Service Federal Credit Union Mr. and Mrs. Michael M. Sowry/ Virtuoso Builders SPS Designs Mimi Sutherland The Rug Store The UPS Store Thyroid and Endocrine Center of South Texas Trinity Press Trinity University United Healthcare Wortham Insurance and Risk Management

VULCAN FUNSHOOT SPONSORS Platinum Team Sponsors ($5,000 +) Bexar Concrete G5 Industrial Services Ryan Construction, Inc. Urban Concrete Valero Marketing and Supply WT Byler

Diamond Team Sponsors ($2,500 +) Alamo Cement Co. Buckley Powder Co. Burlington Northern / BNSF Railway Cemex Gencor Industries HoltCat Lone Star Paving Midstate Environmental Rush Truck Center San Antonio Waukesha-Pearce Industries

Gold Team Sponsors ($1,500 +) Alamo Concrete Products Anthony Machine Applied Industrial Technologies Austin Powder Company Austin Powder Company Bill Hall Trucking Brannan Paving Co, Ltd. Brown Excavation and Utilities Buckley Powder Company

Cancer Therapy & Research Center

n

Annual Report 2016 n

47


California Wired / Unifed Screening and Crushing Capitol Aggregates CEI Enterprises Inc. Clark Construction Curran Contracting Ergon Asphalt and Emulsions E-Z Bel / Ish Garcia GCR Tire Centers Great Northwest Grey Forest Utilities Hydraulic Supply and Service ICPG / Stephen Boudreaux Industrial Electric Service Jebro Kirby Smith Machinery Lone Star Paving Mesa Equipment Nalco P and S Scale Co. Inc. Padgett Stratemann and Co. Paloma Blanca Pape-Dawson PC Concrete Plant Fabricators Inc. PPI Ranch Hand Truckfitters San Antonio Armature Stewart Builders/Keystone Concrete Superior Industries TandD Moravits Texas Lehigh Venture Drilling Supply Venture Drilling / Doosan Heavy Equipment Virgil K. Knowlton Westward Environmental Inc. Williams Supply

Coopers BBQ/Henry and Eva Reil Dews Foundry Doggett Freightliner Doorbrute Doorbrute Railcar Door Closers Doubletree Hotel El Tropicana Hotel Embassy Suites Ergon Asphalt EZ Bel Ford Steel Company GCR Tire Centers Great Northwest Grey Forest Utilities Grey Moss Inn HA Kuehlem Herbst and Associates Hilton Hotel SA Airport Holiday Inn Airport Jebro Jeff and Sharla Lott Jon and Jennifer Peters JW Marriott Lone Star Paving Lytle FFA Milo Abercrombie Orange Corn Company Pat and Denise Bendele Papas Pilar Paul Murry / Mesa Equipment Sauls Seismic, LLC Silver Eagle Distributors Shiner Beer SPAW Glass Suerte Tequila T and D Moravits and Company TPC San Antonio Urban Concrete Vulcan Materials Company

JESSE H. AND SUSAN R. OPPENHEIMER FELLOWSHIP IN NEW ANTICANCER DRUG DEVELOPMENT

Individuals Guy Rogers / KLP Commercial

Sue Oppenheimer /The Jesse H. & Susan Oppenheimer Foundation

Cash and Prize Donations Amber Langley APAC - Texas Inc. Arias Geoprofessionals Bayne Minerals Brett and Cindy Bryant Bridgestone Off-Road Buckley Powder Byron Fischer CDW CMI

48

n

Cancer Therapy & Research Center

BRAIN CANCER RESEARCH Gifts ($2,000 +) Mrs. June Marie Day

Gifts ($200 +)

American Indian Shows Ms. Bettie G. Burton

n

Annual Report 2016

Dr. William Mark Hamilton Mr. and Mrs. Thomas P. McCloskey Mr. and Mrs. Richard B. Stephens Mr. and Mrs. Jerome Robert Weseloh

Gifts ($100 +)

Mrs. Donald S. Akins Mr. Robert Barger Bergheim Volunteer Fire Department Bexar County Kennel Club, Inc Mr. and Mrs. Rick Bodle Ms. Charlotte A. Brown FINRA Mr. and Mrs. Joe B. Fisher Mrs. Connie Gauntt Mr. John Gazlay Mr. and Mrs. A. Jackson Holt Mrs. Lorelei Lord Mr. and Mrs. Dayne C. Luce Mr. Forester J. Mills, Sr. Mr. and Mrs. Eddie Ming Mr. and Mrs. Frank R. Newton Ms. Jennifer Parks Mr. and Mrs. Leslie L. Reichardt, Jr. Mr. James Sands, II Mr. and Mrs. Scott Shaheen Mrs. Linda Sheridan J. D. Stacey Dr. and Mrs. James M. Stedman Mr. Dale Tuttle

Gifts (under $100)

Mrs. Kendra Abbott Ms. Nan Abreu Dr. Jules I. Cahan Ms. Suzanne K. Cobb Mr. and Mrs. Barry Colacurci Mr. and Mrs. Joe A. Crutchfield Mrs. Patricia Denny Mr. and Mrs. Ronald Denny Mr. and Mrs. John Donner Ms. Serita J. Edwards Electro Communication Systems Inc. Mrs. Barbara S. Elia Ms. Regina Goldstein Dr. Coleen Grissom Mr. and Mrs. Jim Hawkins Mrs. Judith Minson Mrs. Stacey Moreno Ms. Marjorie O’Connell Mr. and Mrs. Brad Ramsey

Mr. Alvin Schachtschneider Ms. Marilyn S. Wright Ms. Sandrice L. Zaccardi

BREAST CANCER RESEARCH AND TREATMENT Gifts ($50,000 +) H-E-B

Gifts ($30,000 +) Mrs. Leandra Knes Hallenbeck

Gifts ($10,000 +) CTRC Council Mrs. June Marie Day Saks Fifth Avenue San Antonio

Gifts ($3,000 +) The Edouard Foundation, Inc. Helotes Festival Association, Inc.

Gifts ($100 +)

Mr. and Mrs. Linus L. Baer Mr. and Mrs. Jack E. Calentine Mrs. Nawanda Fuller The Herrmann Family Charitable Foundation Mr. and Mrs. Frank R. Newton Roger L. and Laura D. Zeller Charitable Foundation

CANCER RESEARCH FUND Gifts ($75,000 +) CTRC Council

Gifts ($10,000 +)

Mr. and Mrs. John Brazil Mr. and Mrs. Larry R. Bush Mr. and Mrs. Doyle Dommert Mr. and Mrs. Bill Haywood Mr. and Mrs. David A. Hill Dr. and Mrs. Philip H. Hunke Mr. and Mrs. Frank R. Newton Mr. and Mrs. Mac Northington Mr. and Mrs. Phil Pfeiffer Mr. and Mrs. Richard B. Stephens

Gifts ($5,000 +) Fidelity Charitable Gift Fund Susan G. Komen for the Cure San Antonio


Gifts ($1,000 +) Fraternal Order of Eagles Aerie No. 70 Motor Transport Post 1533 VFW Ms. Linda Tarrant

Gifts ($500 +)

Mr. and Mrs. Ray Cole Fraternal Order of Eagles Aerie No. 70

Gifts (under $500)

Dr. and Mrs. Ronald Addlestone Mr. Ray Nell Batot Mr. and Mrs. Malcolm Gene Chesney Mr. and Mrs. Earl Gene Cutler Ms. Mary Etheridge Mr. and Mrs. Warner F. Fassnidge Mr. David B. Krom Mr. and Mrs. Laird H. McNeil Ms. Elyssa Nicole Mendez Mr. Robert W. Meyer Ms. Carol Wengel

CTRC DIRECTOR’S CRITICAL NEEDS FUND Gifts ($40,000 +)

Mr. and Mrs. Clifton W. Coonrod DEW Foundation

Gifts ($20,000 +) V. H. McNutt Memorial Foundation, Inc. Michael M. Peacock Foundation The USAA Foundation, Inc.

Gifts ($10,000 +) The Parker Foundation, Inc.

Gifts ($2,000 +)

Mr. Edward L. Block Ms. Margery L. Block Davis, Cedillo and Mendoza, Inc. San Antonio Area Foundation Wells Fargo Community Support

Gifts ($1,000 +)

Estate of Jay L. Adelman Benevity Community Impact Fund AT&T Services, Inc. (PACs) Mr. and Mrs. Steve Alfonso Chiscano Mr. and Mrs. Louis I. Erdos Lantern Pharma Inc. Mr. and Mrs. Michael J. Novak Mr. and Mrs. Carl A. Register

Mr. and Mrs. Stanley D. Rosenberg Mrs. Karen Salsman The Doctors Donna and Ian Thompson

Gifts ($500 +)

AnArte Gallery Bank of America Employee Giving Campaign Boeing Company Employee Individual Giving Program Dr. Roxanne Carmichael-Rosales CFC of San Antonio Area Colonel (Ret.) and Mrs. Kenneth E. Crow Ms. Susan Kay Davidson Gorrondona and Associates, Inc. Mr. Michael McRobert Harris K. and Lois G. Oppenheimer Foundation Mr. and Mrs. Michael G. Othites Mr. and Mrs. Stanley D. Rosenberg Dr. John C. Sparks, Sr. Mr. and Mrs. Jeffrey Train Truist

Gifts ($200 +)

Mr. and Mrs. James F. Beck Braverman Family Charitable Foundation Dr. James M. Brennan Mr. Roy W. Classen Colonel (Ret.) Harvey Crouch Exelon Corporation Mrs. Shai Frietze Mrs. Viola Godines Mr. and Mrs. Jaime D. Goodwin Mr. and Mrs. Roger R. Hemminghaus Mr. and Mrs. Edward B. Kelley Kerrville Public Utility Board LeafGuard by Beldon, Inc. Mr. Erik Linstrom Dr. and Mrs. Michael S. McArthur Mr. and Mrs. William J. Merrill Lieutenant Colonel (Ret.) Roger E. Miller Mr. Leonard O’Donnell Mr. Bradley Perkins Mr. and Mrs. Richard G. Reiss, Jr. Mr. and Mrs. Jack Rips Mr. and Mrs. Leonardo Salinas Ms. Lois L Samford San Antonio Propeller Mr. and Mrs. Mark H. Wright

Gifts ($100 +)

Mr. and Mrs. J. Scott Beckendorf Ms. Tracy B. Braymen Mr. and Mrs. Stephen Brown

Dr. and Mrs. C.F. Cathcart Ms. Yolanda Cheves Dr. Mary Choi Ms. Isabel Christian Cordillera Ranch, LTD. Cram Roofing Company, Inc. Ms. Alice S. Crawford Mr. and Mrs. Jack Dampf Mr. and Mrs. Charles H. Davis Mr. John T. Dorbandt Mr. David H. Drake and Ms. Mae Ladoux Mrs. America Farrell Mr. William E. Fox, Jr. Dr. and Mrs. Adam Craig Gold Ms. Jillian Gomez Ms. Rebecca B. Hallock-Wolff Mr. and Mrs. Donald B. Harrell Ms. Natasha Hartrick Mrs. Mary Teresa Hatten Mr. Robert J. Hayden Ms. Sandra Hegyesi Mrs. Amy Hilburn Mr. Jared Holcomb Mr. and Mrs. Henry C. Irvin Mrs. Shirley C. Janecek Mr. Dennis Johnson Ms. Sharlene J. Jordan Mr. and Mrs. John L. Kauth, III Ms. Patricia A. Kempf Mr. and Mrs. Dennis Kendricks Mr. Jerry L Knippa Mr. Martin Kramer L and M Steel Co., Inc. Mr. and Mrs. Robert E. Laxson Leco Management Mrs. Lori Lunder Mr. and Mrs. Richard Mannheimer Mr. and Mrs. Randall H. Mason Mrs. Patricia McNeil Dr. Catherine Theresa Milbourn and Mr. John Milbourn Mr. and Mrs. Melvin Mitchell Mrs. Virginia Evers Mohr Mr. Albert C. Molter, Jr. Mr. and Mrs. Roger Nasr Mr. and Mrs. Chris Niederkrom Mrs. Lori O’Connell Ms. Marilyn M. O’Hair Mr. David Overpeck Mrs. Julie Pack Mr. and Mrs. William A. Parker, Sr. Penfed Credit Union Ms. Terry Jo Phillips Mr. and Mrs. Ronald Rhea Rushing Mr. and Mrs. Ed Santiago Ms. Patricia S. Schendel

Mr. and Mrs. Steve Schindler Colonel (Ret.) Charles Scott Ms. Laura Shock Mr. Walter Sirotiak Mr. Duke Smith Versar Center Mr. Jess Clark Ward, III Ms. Karen Groff Wendel

Gifts (under $100)

Ackermann Ranch and Farm, LP Ms. Yvonne L. Alberthal Ms. Patricia S. Allen Mrs. Nena Allevato Mrs. Nancy Fix Anderson Mr. and Mrs. Emerson Banack, Jr. Mr. and Mrs. Bruce R. Barthhold Mr. Jonathan Bartlett Mrs. Denise J. Beverage Bexar Appraisal District SMSGT James E. Birkner and Ms. Robyn E. Becak Mr. and Mrs. Stephen Howard Blount Mr. and Mrs. Richard J. Breitlow Ms. Elizabeth T Brissette Dr. Daphne Brown Ms. Elvira M. Castro Mrs. Patricia A. Cavanaugh Mr. and Mrs. Sam Center Mr. and Mrs. Tom Chegin Ms. Kathleen Cobb Colorado Springs Amateur Hockey Association Mrs. Cherry Connell Mr. and Mrs. Daniel C. Courson Ms. Shirley M. Crane Ms. Alice S. Crawford Ms. Karen Cupples Ms. Vivian S. Dable Ms. Julianne D’Amore Mr. John A. Daniels (deceased) Mr. Jonathan Daniszewski Mr. Michael D. Davis Mr. and Mrs. Randall Koppel Davis Mr. and Mrs. C.D. Dennis Ms. Jennifer DuBose Ms. Nan L. Durand Mrs. Cheryl L. Dwyer Mrs. Lisa Edelman Mr. and Mrs. Harry W. Ehlers Exelon Corporation Ms. Mary Beth Fournier Mrs. Bertie K. Frank Ms. Erika Michelle Gamez Ms. Lindsay Garcia Mr. and Mrs. Karl W. George

Cancer Therapy & Research Center

n

Annual Report 2016 n

49


Mrs. Geraldine Gillespie Mr. and Mrs. Lukin T. Gilliland Ms. Sarah Lee Gilliland Ms. Cecile H. Gloier Ms. Gloria Estela Grajeda Ms. Kelley Lynn Green Mr. and Mrs. Alan Gugenheim Mr. and Mrs. Jimmy E. Guillot Mr. and Mrs. Emmett R. Hall Mr. and Mrs. Bruce Hendin Mr. and Mrs. Charles E. Herrera Ms. Dorene Herzog Mr. Tres Hewell Mr. Paul D. Hill Mr. and Mrs. Sidney Hodges Mrs. Mary Johns Mr. and Mrs. William A. Johnson Ms. Janet Annabelle Jones Mr. and Mrs. Ergun Kahramanoglu Mr. and Mrs. John Hubert Keller Mr. and Mrs. Burton King Ms. Kathy Knight Mr. and Mrs. Robert P. Koenig Mrs. Judith R. Lachman Mr. Brian Lagunas Mr. and Mrs. Billy D. Langley Ms. Willene Leeder Mrs. Jeanette M. Lowell Mr. and Mrs. Gerald Reese Mathis Mr. Fred C. Delaney and Ms. Patricia J. McCarroll Ms. Laura McCoy Mrs. Annabelle A. McGee Mr. C. David McGinnis Mr. and Mrs. John McKinney Dr. and Mrs. Thomas M. McNish Dr. and Mrs. Charles Murph Melton Mr. and Mrs. Michael Met Mrs. Judith Minson Miss Grace Minus Ms. Yasmin Mistry Mr. and Mrs. Alton Moczygemba Mr. Lance Modawell Mr. and Mrs. Harvey Moellering Mrs. Virginia Evers Mohr Mrs. Nancy Moore Mr. and Mrs. Juan B. Morales Mr. and Mrs. Wade Morrison Mr. and Mrs. Daniel Mota Ms. Mary K. Napier Mr. and Mrs. Gary Glenn Nixon Ms. Maria Nora Olivarez Mr. David A. Padilla Mr. and Mrs. David J. Palans Mr. and Mrs. Glenn Partlin Patient’s Premier Choice, LLC

50

n

Mr. and Mrs. Charles T. Patrick Mr. David Perry Ms. Reita P. Phillips Dr. Guy D. Plunkett Mrs. Donia Rankin Real Estate Advisory Team Mr. and Mrs. Monty Rogers Mr. and Mrs. Lee J. Rosenberg Mr. David Sanchez Ms. Melissa Sanchez Ms. Uttara M. Sawant Mr. and Mrs. David Schmidtzinsky Mr. and Mrs. Charles C. Schwartz Mrs. Linda N. Seeligson Mr. and Mrs. Ben Smith, III Mr. and Mrs. Phillip R. Spicer, Jr. Ms. Madeline Stacy Dr. and Mrs. James M. Stedman Ms. Mary Stich Mr. and Mrs. Kenneth Sugarman Mr. and Mrs. Mike Thomas Mr. and Mrs. Arthur A. Tolbert, Jr. Mr. and Mrs. Henry C. Trotter Mrs. Aurline Tschirhart Mrs. Loretta M. Tuck Ms. Lisa Veraza Mrs. Catherine G. Vetters Mr. and Mrs. John G. Wernette Mr. and Mrs. Charlie Whipple Mr. James T. White Ms. Theresa G. Wilson Mr. John Withington Dr. and Mrs. Hugh L. Wolff Mr. and Mrs. Jon C. Wood Mr. and Mrs. John W. Woody Dr. and Mrs. James William Yancy

Gifts (under $100) Mr. Alex Drabant Missouri Valley, Inc.

INSTITUTE FOR DRUG DEVELOPMENT Gifts ($10,000 +) City of Schertz

Gifts ($5,000 +) J.C. Heyser and Irene H. Heyser Memorial Fund

Gifts ($300 and under)

Mrs. Elizabeth W. Adamson Trust CTRC Council Mr. Michael C. Fisher

LUNG CANCER RESEARCH Gifts ($2,000 +) Mrs. June Marie Day

PATIENT ASSISTANCE FUND Gifts ($100,000 +) CTRC Council

Gifts ($5,000 +) Phyllis Browning Company Dr. Yolanda Escobedo and Mr. Dan Escobedo St. Luke’s Lutheran Health Ministries, Inc. The Watson Foundation

Gifts ($1,000 +)

Mr. Brian Mitchell

The American Society For Therapeutic Radiology/Oncology, Inc Estate of Jerry Craft Mr. David E. Kehl Mr. Jon H. Smith Warm Springs Foundation

Gifts ($100 +)

Gifts ($500 +)

GENITOURINARY CANCER RESEARCH AND TREATMENT Gifts ($1,000 +)

Aaron Concrete Contractors, LP Amber Electrical Contractors, Inc. Anthony Bedford Burkett Enterprises J.E. Carlson, Inc. Davis Brothers Construction Janet Grojean Mrs. Pat Guzzardo Plains Plumbing Company, Inc., LLC Tommie White

Cancer Therapy & Research Center

n

Annual Report 2016

Mr. Ron Entrekin Dr. and Mrs. Floyd Wright Hartsell Ms. Linda T. Hummel Impact 4 Good LLC Ms. Deborah K. Ivy Markaire, Inc. Mr. Fred C. Delaney and Ms. Patricia J. McCarroll Mr. and Mrs. Douglas H. Raney Mr. and Mrs. Barry L. Rupert UTHSCSA Department of Pathology Various Donors Dr. and Mrs. James William Yancy Mr. and Mrs. Vaughn Zimmerman

Gifts (under $100) Mr. and Mrs. Frank Bernosky Ms. Joan P. Bohl Mr. and Mrs. Jerry Boothby Dr. and Mrs. J. Brant Ellis Mr. and Mrs. Lawrence D. Goldsmith Mrs. Burton E. Grossman Dr. and Mrs. Leslie David Hillis Mr. and Mrs. Jeffrey Jost Mrs. Eunice Kuehl Mr. and Mrs. Edwin D. McLeod Ms. Linda R. Rodriguez Mr. William J. Sanns Mr. and Mrs. Stephen Paul Scales Dr. Laura Tenner

RENOVATIONS FUND Gifts ($10,000 +) Mr. and Mrs. James H. Cowden

TRIBUTE PROGRAM FUNDS James John Bernsen Memorial Fund Mr. Michael Glatz Mr. Ven Shanmugam

Jennifer Marie Vargas Brain Cancer Research Fund

Ms. Cheryl L. Blalock Miss Carolyn J. Clark Mr. and Mrs. Charles H. Davis Mr. and Mrs. Jean Pierre Lair The Doctors Donna and Ian Thompson

Ms. Evonne Soto

Gifts ($100 +)

Karen and Ronald Herrmann Breast Cancer Program Fund

Biodynamic Research Corporation Mr. and Mrs. Richard J. Cavazos Mrs. James M. Cavender, III Mr. and Mrs. A. Baker Duncan, III

Karen and Ronald Herrmann Bladder Cancer Program Fund Mr. and Mrs. J. Scott Beckendorf Mr. and Mrs. Mark J. Berridge

Mr. and Mrs. J. Scott Beckendorf Mr. and Mrs. Mark J. Berridge


November 1974 CTRC opens as a free-standing regional cancer treatment center focused on radiation therapy.

October 2016 CTRC is one of only four NCI-Designated Cancer Centers in Texas.


Virginia Kaklamani, M.D., director of the CTRC Breast Cancer Program, with her patient.

witter Icon THE ONLY NCI-DESIGNATED CANCER CENTER IN SOUTH TEXAS. 210-450-1000 Follow us online at www.ctrc.net Facebook “f ” Logo

CMYK / .ai

Facebook “f ” Logo

CMYK / .ai

Make a gift to the CTRC uthscsa.edu/patient-care/ctrc/donate


Cancer Therapy & Research Center (CTRC) Annual Report 2016